Advertisement

Systemic Lupus Erythematosus

  • Jerry C. Jacobs

Abstract

It was 1954. A 13-year-old girl became ill with fever, arthritis, a butterfly facial rash, diplopia, alopecia, and subcutaneous nodules (Fig. 5.1). Her urinalysis showed some protein and 20 red blood cells. A diagnosis of systemic lupus erythematosus (SLE) was made, and treatment was begun with 50 mg of prednisone daily. There was a dramatic response, and she began to feel well. Her chart was filled with notes of concern about the potential fearsome side effects of prednisone and its merely palliative benefits. As soon as she felt a little better, her doctors would reduce the prednisone; she would promptly become ill again. During the 21 months she survived, she was continuously ill and was hospitalized 10 times for a total 220 hospital days before she died of renal failure.

Keywords

Lupus Nephritis Mixed Connective Tissue Disease Systemic Lupus Erythema Congenital Heart Block Subacute Cutaneous Lupus Erythematosus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Good RA, Venters H, Page AR, et al.: Diffuse connective tissue diseases in childhood. Lancet 81: 192–204, 1961.Google Scholar
  2. 2.
    Morrow WJW, Youinou P, Isenberg DA, Snaith ML: Systemic lupus erythematosus: 25 years of treatment related to immunopathology. Lancet 2: 206–210, 1983.CrossRefPubMedGoogle Scholar
  3. 3.
    Steinberg AD, Raveche ES, Laskin CA, et al.: Systemic lupus erythematosus: Insights from animal model. Ann Intern Med 100: 714–727, 1984.CrossRefPubMedGoogle Scholar
  4. 4.
    Decker JL, Steinberg AD, Reinertsen JL, et al.: Systemic lupus erythematosus: Evolving concepts. Ann Intern Med 94: 587–604, 1979.CrossRefGoogle Scholar
  5. 5.
    Ko$ler D: Systemic lupus erythematosus. Scientific American, July 1980, pp. 52–61.Google Scholar
  6. 6.
    Reveille JD, Schrohenloher RE, Acton RT, Barger BO: DNA analysis of HLADR and DQ genes in American blacks with systemic lupus erythematosus. Arthritis Rheum 32: 1243–1251, 1989.CrossRefPubMedGoogle Scholar
  7. 7.
    Smolen JS, Chused TM, Leiserson WM, et al.: Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Correlation with clinical features. Am J Med 72: 783–790, 1982.CrossRefPubMedGoogle Scholar
  8. 8.
    Stohl W, Crow MK, Kunkel HG: Systemic lupus erythematosus with deficiency of the T4 epitope on T helper/inducer cells. N Engl J Med 312: 1671–1678, 1985.CrossRefPubMedGoogle Scholar
  9. 9.
    Jacobs JC: Systemic lupus erythematosus in childhood. Pediatrics 32: 257–264, 1963.PubMedGoogle Scholar
  10. 10.
    Meislin AG, Rothfield N: Systemic lupus erythematosus in childhood. Pediatrics 42: 37–49, 1968.PubMedGoogle Scholar
  11. 11.
    Waldavens PA, Chase P: The prognosis of childhood systemic lupus erythematosus. Am J Dis Child 130: 929–933, 1976.Google Scholar
  12. 12.
    King KK, Kornreich HK, Bernstein BH, et al.: The clinical spectrum of systemic lupus erythematosus in childhood. Arthritis Rheum 20: 287–294, 1977.PubMedGoogle Scholar
  13. 12a.
    Winchester RJ, Nunez-Roldan A. Some genetic aspects of SLE. Arthritis Rheum 25: 833–837, 1982.CrossRefPubMedGoogle Scholar
  14. 12b.
    Shoenfeld Y, Slor H, Shafrir S, et al.: Diversity and pattern of inheritance of autoantibodies in families with multiple cases of systemic lupus erythematosus. Ann Rheum Dis 51: 611–618, 1992.Google Scholar
  15. 13.
    Norris DG, Colon AR, Stickler GB: Systemic lupus erythematosus in children. Clin Pediatr 16: 774–778, 1977.CrossRefGoogle Scholar
  16. 14.
    Cassidy JT, Sullivan DB, Petty RE, et al.: Lupus nephritis and encephalopathy: Prognosis in 58 children. Arthritis Rheum 20: 315–322, 1977.PubMedGoogle Scholar
  17. 15.
    Fish AJ, Blau EB, Westberg NG, et al.: Systemic lupus erythematosus within the first two decades of life. Am J Med 62: 99–117, 1977.CrossRefPubMedGoogle Scholar
  18. 16.
    Masi AT, Kaslow RA: Sex effects in systemic lupus erythematosus. Arthritis Rheum 21: 480–484, 1978.CrossRefPubMedGoogle Scholar
  19. 17.
    Siegel M, Lee SL: The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum 3: 1–54, 1973.CrossRefPubMedGoogle Scholar
  20. 18.
    Lahita RG, Chiorazzi N, Gibofsky A, et al.: Familial systemic lupus erythematosus in males. Arthritis Rheum 26: 39–44, 1983.CrossRefPubMedGoogle Scholar
  21. 19.
    Kaslow RA, Masi AT: Age, sex, and race effects on mortality from systemic lupus erythematosus in the United States. Arthritis Rheum 21: 473–484, 1978.CrossRefPubMedGoogle Scholar
  22. 20.
    Wallace DJ, Hahn BH (eds.): Dubois’ Lupus Erythematous, 4th ed. Lee and Febiger, Philadelphia, 1993.Google Scholar
  23. 21.
    Deapen D, Escalante A, Weinrib L, et al.: A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35: 311–18, 1992CrossRefPubMedGoogle Scholar
  24. a.Reichlin M, Harley JB, Lockshin MD: Serologic studies of monozygotic twins with systemic lupus erythematosus. Arthritis Rheum 35: 457–64, 1992.CrossRefGoogle Scholar
  25. 22.
    Arnett FC, Shulman LE: Studies in familial systemic lupus erythematosus. Medicine 55: 313–322, 1976.CrossRefPubMedGoogle Scholar
  26. 23.
    Kaplan D: The onset of disease in twins and siblings with systemic lupus erythematosus. J Rheumatol 11: 648–652, 1984.PubMedGoogle Scholar
  27. 24.
    Scherak O, Smolen JS, Mayr WR: HLA-DRw3 and systemic lupus erythematosus. Arthritis Rheum 23: 954–957, 1980.CrossRefPubMedGoogle Scholar
  28. 25.
    Cleland LG: Familial lupus: Family studies of HLA and serologic findings. Arthritis Rheum 21: 183–191, 1978.CrossRefPubMedGoogle Scholar
  29. 26.
    Reville JO, Bias WB, Winkelstein JA, et al.: Familial systemic lupus erythematosus: Immunogenetic studies in eight families. Medicine 62: 21–35, 1983.Google Scholar
  30. 27.
    Pronek Z, Timmerman LA, Alper CA, et al.: Major histocompatibility complex genes and susceptibility to systemic lupus erythematosus. Arthritis Rheum 33: 1542–1553, 1990.CrossRefGoogle Scholar
  31. 28.
    Morris RJ, Freed CR, Kohler PE: Drug acetylation phenotype unrelated to development of spontaneous systemic lupus erythematosus. Arthritis Rheum 22: 777–780, 1979.CrossRefPubMedGoogle Scholar
  32. 29.
    Reidenberg MM, Levy M, Drayer DE, et al.: Acetylator phenotype in idiopathic systemic lupus erythematosus. Arthritis Rheum 23: 569–573, 1980.CrossRefPubMedGoogle Scholar
  33. 30.
    Oritz Neu C, LeRoy EC: The coincidence of Klinefelter’s syndrome and systemic lupus erythematosus. Arthritis Rheum 12: 241–246, 1969.CrossRefGoogle Scholar
  34. 31.
    Schopper K, Feldges A, Baerlocher K, et al.: Systemic lupus erythematosus in Staphylococcus aureus hyperimmunoglobulinaemia E syndrome. Br Med J 287: 524–526, 1983.CrossRefGoogle Scholar
  35. 32.
    Rosemarin JI, Nigro EJ, Levere RD, Mascarenhas: Systemic lupus erythematosus and acute intermittent porphyria: Coincidence or association? Arthritis Rheum 25: 1134–1137, 1982.CrossRefPubMedGoogle Scholar
  36. 33.
    Sakane T, Steinberg AD, Green I: Studies of immune functions of patients with systemic lupus erythematosus. Arthritis Rheum 23: 225–231, 1980.CrossRefPubMedGoogle Scholar
  37. 34.
    Ruiz-Arguelles A, Alarcon-Segovia D, Llorenie L, et al.: Heterogeneity of the spontaneously expanded and mitogen-induced generation of suppressor cell function of T cells on B cells in systemic lupus erythematosus. Arthritis Rheum 23: 1004–1009, 1980.CrossRefPubMedGoogle Scholar
  38. 35.
    Unanue ER: Cooperation between mononuclear phagocytes and lymphocytes in immunity. N Engl J Med 303: 977–985, 1980.CrossRefPubMedGoogle Scholar
  39. 36.
    Frank MM, Hamburger MI, Lawley TJ, et al.: Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 300: 518–523, 1979.CrossRefPubMedGoogle Scholar
  40. 37.
    Inman RD: Immunologic sex differences and the female preponderance in systemic lupus erythematosus. Arthritis Rheum 21: 849–852, 1978.CrossRefPubMedGoogle Scholar
  41. 38.
    Jungers P, Dougados M, Pelissier C, et al.: Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 25: 618623, 1982.Google Scholar
  42. 39.
    Lahita RG, Bradlow HL, Ginzler E, et al.: Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 30: 241–247, 1987.CrossRefPubMedGoogle Scholar
  43. 40.
    Morley KD, Parke A, Hughes GRV: Systemic lupus erythematosus: Two patients treated with danazol. Br Med J 284: 1431–1432, 1982.CrossRefGoogle Scholar
  44. 41.
    DeHoratius RJ, Messner RP: Lymphocytotoxic antibodies in family members of patients with systemic lupus erythematosus. J Clin Invest 55: 1254–1258, 1975.CrossRefPubMedGoogle Scholar
  45. 42.
    Folomeeva O, Nassonova VA, Alekberova AS: Comparative studies of antilymphocyte, antipolynucleotide, and antiviral antibodies among families of patients with systemic lupus erythematosus. Arthritis Rheum 21: 23–27, 1978.CrossRefPubMedGoogle Scholar
  46. 43.
    Miller KB, Schwartz RA: Familial abnormalities of suppressor-cell function in systemic lupus erythematosus. N Engl J Med 301: 803–809, 1979.CrossRefPubMedGoogle Scholar
  47. 44.
    Messner RP, DeHoratius R, Ferrone S: Lymphocytotoxic antibodies in systemic lupus erythematosus patients and their relatives. Arthritis Rheum 23: 265–270, 1980.CrossRefPubMedGoogle Scholar
  48. 45.
    Seibold JR, Lynch CJ: Disco lupus, a new disease syndrome (letter). Arthritis Rheum 23: 962–963, 1980.CrossRefPubMedGoogle Scholar
  49. 46.
    Wysenbeek AJ, Block DA, Fries JF: Prevalence and expression of photosensitivity in systemic lupus erythematosus. Ann Rheum Dis 48: 461–463, 1989.CrossRefPubMedGoogle Scholar
  50. 47.
    Dowdy MJ, Nigra TP, Barth WF: Subacute cutaneous lupus erythematosus during Puva therapy for psoriasis: case report and review of the literature. Arthritis Rheum 32:343–346, 1989 (see also Correspondence 33: 302–303, 1990 ).Google Scholar
  51. 48.
    Tan EM: Sunlight as a potential etiological factor in systemic lupus erythematosus. In Hughes GRV (ed.) Modern Topics in Rheumatology. Heinemann, London, 1976, pp. 99–106.Google Scholar
  52. 49.
    LeFeber WP, Norris DA, Ryan SR, et al.: Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes. J Clin Invest 74: 1545–1551, 1984.CrossRefPubMedGoogle Scholar
  53. 50.
    Agnello V: Complement deficiency states. Medicine 57: 1–23, 1978.CrossRefPubMedGoogle Scholar
  54. 50a.
    Johnson CA, Densen P, Wetsel RA et al Molecular heterogeneity of C2 deficiency. N Engl J Med 326: 871–874, 1992.CrossRefPubMedGoogle Scholar
  55. 50b.
    Nilsson UR, Nilsson B, Storm K-E, et al.: Hereditary dysfunction of the third component of complement associated with a systemic lupus erythematosus-like syndrome and meningococcal meningitis. Arthritis Rheum 35: 580–586, 1992.Google Scholar
  56. 51.
    Zeitz HJ, Miller GW, Lint TF, et al.: Deficiency of C7 with systemic lupus erythematosus. Arthritis Rheum 24: 87–93, 1981.CrossRefPubMedGoogle Scholar
  57. 52.
    Colten HR, Alper CA, Rosen FS: Genetics and biosynthesis of complement proteins. N Engl J Med 304: 653–656, 1981.CrossRefPubMedGoogle Scholar
  58. 53.
    Fielder AHL, Walport MJ, Batchelor JR, et al.: Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: Importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J 286: 425–428, 1983.CrossRefGoogle Scholar
  59. 54.
    Hannema AJ, Kluin-Nelemans JC, Hack CE, et al.: SLE like syndrome and functional deficiency of CIq in members of a large family. Clin Exp Immunol 55: 106–114, 1984.PubMedGoogle Scholar
  60. 55.
    Wilson JG, Fearon DT: Altered expression of complement receptors as a pathogenetic factor in systemic lupus erythematosus. Arthritis Rheum 27: 1321 1328, 1984.Google Scholar
  61. 56.
    Wisnieski JJ, Naff GB, Pensky J, Sorin SB: Terminal complement component deficiencies and rheumatic disease: development of a rheumatic syndrome and anticomplementary activity in a patient with complete C6 deficiency. Ann Rheum Dis 44: 716–722, 1985.CrossRefPubMedGoogle Scholar
  62. 57.
    Howard PF, Hochberg MC, Bias WB, et al.: Relationship between C4 Null genes. HLA-D region antigens, and genetic susceptibility to systemic lupus erythematosus in Caucasian and Black Americans. Am J Med 81: 187–193, 1986.CrossRefPubMedGoogle Scholar
  63. 57a.
    Suzuki Y, Ogura Y, Otsubo O, et al.: Selective deficiency of C is associated with a systemic lupus erythematosus-like syndrome. Report of a case. Arthritis Rheum 35: 576–579, 1992.Google Scholar
  64. 58.
    Lockshin MD, Qamar T, Redecha P, Harpel PC: Hypocomplementemia with Cls-CI inhibitor complex in systemic lupus erythematosus. Arthritis Rheum 29: 1467–1472, 1986.CrossRefPubMedGoogle Scholar
  65. 59.
    Taieb A, Hehunstre J-P, Goetz J, et al.: Lupus erythematosus panniculitis with partial genetic deficiency of C2 and C4 in a child. Arch Dermatol 122: 576–582, 1986.CrossRefPubMedGoogle Scholar
  66. 60.
    Antes U, Heinz H-P, Loss M: Evidence for the presence of autoantibodies to the collagen-like portion of Clq in systemic lupus erythematosus. Arthritis Rheum 31: 457–464, 1988.CrossRefPubMedGoogle Scholar
  67. 61.
    Steinsson K, Erlendsson K, Valdimarsson H: Successful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months. Arthritis Rheum 32: 906–913, 1989.PubMedGoogle Scholar
  68. 62.
    Nusinow SR, Zuraw BL, Curd JG: The hereditary and acquired deficiencies of complement. Med Clin Nor Am 69: 487–504, 1985.Google Scholar
  69. 63.
    Hauptmann G: Frequency of complement deficiencies in man; disease associations and chromosome assignment of complement genes and linkage groups. Complement Inflamm 6: 74–80, 1989.PubMedGoogle Scholar
  70. 64.
    Foeldvari I, Kimura Y, Jacobs JC: Congenital complement deficiency in childhood lupus: 17% require little or no treatment. Arthritis Rheum 33S: 144, 1990.Google Scholar
  71. 65.
    Kahl LE, Atkinson JP: Autoimmune aspects of complement deficiency. Clin Aspects Autoimmunity 2: 8–20, 1988.Google Scholar
  72. 66.
    Wilson CB, Dixon FJ: Immunologic mechanisms in nephritogenesis. Hosp Pract 14: 57–69, 1979.PubMedGoogle Scholar
  73. 67.
    Couser WG: What are circulating immune complexes doing in glomerulonephritis? N Engl J Med 304: 1230–1232, 1981.CrossRefPubMedGoogle Scholar
  74. 68.
    Waller SJ, Taylor RP, Wright EL, et al.: DNA/anti-DNA complexes. Arthritis Rheum 24: 651–657, 1981.CrossRefPubMedGoogle Scholar
  75. 69.
    Panem S, Ordonez NG, Kirstein WH, et al.: C-type virus expression in sytemic lupus erythematosus. N Engl J Med 295: 470–475, 1976.CrossRefPubMedGoogle Scholar
  76. 70.
    Phillips PE: Viruses and systemic lupus erythematosus. Bull Rheum Dis 28: 954–958, 1978.Google Scholar
  77. 71.
    Abrass CK, Nies KM, Louie JS, et al.: Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 23: 273–282, 1980.CrossRefPubMedGoogle Scholar
  78. 72.
    Yang LC, Norman ME, Doughty RA: A micromethod for the analysis of cryoglobulins via laser nephelometry: evaluation in comparison to Ciq binding activity in autoimmune diseases in pediatrics. Pediatr Res 14: 858–862, 1980.PubMedGoogle Scholar
  79. 73.
    Lange K, Ores R, Strauss W, et al.: Steroid therapy of systemic lupus erythematosus based on immunologic considerations. Arthritis Rheum 8: 244–259, 1965.CrossRefPubMedGoogle Scholar
  80. 74.
    Gewurz H, et al.: The complement profile in acute glomerulonephritis, systemic lupus erythematosus and hypocomplementemic chronic glomerulonephritis. Contrasts and experimental correlations. Int Arch Allergy Appl Immunol 34: 556–570, 1968.CrossRefPubMedGoogle Scholar
  81. 75.
    Kohler PF, Ten Besel R: Serial complement component alterations in acute glomerulonephritis and systemic lupus erythematosus. Clin Exp Immunol 4: 191–202, 1969.PubMedGoogle Scholar
  82. 76.
    Ruddy S, Carpenter CB, Chin KW, et al.: Human complement metabolism: an analysis of 144 studies. Medicine 54: 165–178, 1975.Google Scholar
  83. a.Ricker DM, Hebert LA, Rohde, et al.: Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are C4 levels. Am J Kid Dis 18:678–685, 1991. (See also: Editorial pp. 686–688.)Google Scholar
  84. 77.
    Takemura S, Hotta T, Matsumura N, et al.: Cold activation of complement. Arthritis Rheum 25: 1138–1140, 1982.CrossRefPubMedGoogle Scholar
  85. 78.
    Abramson SB, Weissmann G: Complement split products and the pathogenesis of SLE. Hosp Pract pp. 45–56, December 15, 1988.Google Scholar
  86. 79.
    Pisetsky DS: The role of anti-DNA antibodies in systemic lupus erythematosus. Clin Aspects of Autoimmunity 2: 8–15, 1988.Google Scholar
  87. 80.
    Schur PH, Carr RI, Kunkel HG: Desoxyribonuclease acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 45: 1732–1740, 1966.CrossRefPubMedGoogle Scholar
  88. 81.
    Pincus T, Schur PH, Rose JA, et al.: Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med 281: 701–705, 1969.CrossRefPubMedGoogle Scholar
  89. 82.
    Hughes GRV: Significance of anti-DNA antibodies in systemic lupus erythematosus. Lancet 2: 861–863, 1971.CrossRefPubMedGoogle Scholar
  90. 83.
    Pincus T, Hughes GRV, Pincus D, et al.: Antibodies to DNA in childhood systemic lupus erythematosus. J Pediatr 78: 981–984, 1971.CrossRefPubMedGoogle Scholar
  91. 84.
    Weinstein A, Bordwell B, Stone B, et al.: Antibodies to native DNA and serum complement (C3) levels. Application to diagnosis and classification of systemic lupus erythematosus. Am J Med 74: 206–216, 1983.CrossRefPubMedGoogle Scholar
  92. 85.
    Koffler D, Agnello V, Winchester R, et al.: The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. J Clin Invest 52: 198–204, 1973.CrossRefPubMedGoogle Scholar
  93. 86.
    Lightfoot RW, Hughes GRV: Significance of persisting serologic abnormalities in systemic lupus erythematosus. Arthritis Rheum 19: 837–843, 1976.CrossRefPubMedGoogle Scholar
  94. 87.
    Appel AE, Sablay LB, Golden RA, et al.: The effect of normalization of serum complement and anti-DNA antibody on the course of lupus nephritis. Am J Med 64: 274–283, 1978.CrossRefPubMedGoogle Scholar
  95. 88.
    Adler MK, Baumgarten A, Hecht B, et al.: Prognostic significance of DNA-binding capacity patterns in patients with lupus nephritis. Ann Rheum Dis 34: 444–450, 1975.CrossRefPubMedGoogle Scholar
  96. 89.
    Winfield JB, Brunner CM, Koffler D: Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. Arthritis Rheum 21: 289–294, 1978.CrossRefPubMedGoogle Scholar
  97. 90.
    Cohen AS, Reynolds WE, Franklin EC, et al.: Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 21: 643–648, 1971.Google Scholar
  98. 91.
    Saulsbury FT, Sabio H, Conrad D, et al.: Acute leukemia with features of systems lupus erythematosus. J Pediatr 105: 57–59, 1984.CrossRefPubMedGoogle Scholar
  99. 92.
    Lehman TA, Hanson V, Singsen B, et al.: Serum complement abnormalities in the antinuclear antibody-positive relatives of children with systemic lupus erythematosus. Arthritis Rheum 22: 954–958, 1979.CrossRefPubMedGoogle Scholar
  100. 93.
    Tsokos GC, Pillemer SR, Klippel JH: Rheumatic disease syndrome associated with antibodies to the Ro (SS-A) ribonuclear protein. Semin Arthritis Rheum 16: 237–244, 1987.CrossRefPubMedGoogle Scholar
  101. 94.
    Gladman DD, Chalmers A, Urowitz MB: Systemic lupus erythematosus with negative lupus erythematosus cells and antinuclear factor. J Rheum 4: 142–147, 1978.Google Scholar
  102. 95.
    Jordan SC, Lemire JM, Broder W, et al.: False-negative anti-DNA antibody activity in infantile systemic lupus erythematosus (SLE). J Clin Immunol 4: 156–162, 1984.CrossRefPubMedGoogle Scholar
  103. 96.
    Rothschild BM, Jones JV, Chesney C, et al.: Relationship of clinical findings in systemic lupus erythematosus to seroreactivity. Arthritis Rheum 26: 45–51, 1983.CrossRefPubMedGoogle Scholar
  104. 97.
    Sequi J, Leigh I, Isenberg DA: Relation between antinuclear antibodies and the autoimmune rheumatic diseases and disease type and activity in systemic lupus erythematosus using a variety of cultured cell lines. Ann Rheum Dis 50: 167172, 1991.Google Scholar
  105. 98.
    Fritzler MJ: Antinuclear antibodies in the investigation of rheumatic diseases. Bull Rheum Dis 35 (6): 1–10, 1985.PubMedGoogle Scholar
  106. 99.
    Harley JB, Sestak AL, Willis LG, et al.: A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum 32: 826–836, 1989.PubMedGoogle Scholar
  107. 100.
    Lehman TJA, Reichlin M, Santner TJ, et al.: Maternal antibodies to Ro (SSA) are associated with both early onset of disease and male sex among children with systemic lupus erythematosus. Arthritis Rhuem 32: 1414–1420, 1989.CrossRefGoogle Scholar
  108. 101.
    Reichlin M, Harley JB: Antibodies to Ro(SSA) and the heterogeneity of systemic lupus erythematosus. J Rheumatol 14:(Suppl)112–117, 1987.Google Scholar
  109. 102.
    Cabral DA, Petty RE, Fung M, Malleson PN: Persistent antinuclear antibodies in children without identifiable inflammatory rheumatic or autoimmune disease. Pediatrics 89: 441–444, 1992.PubMedGoogle Scholar
  110. 103.
    Chudwin DS, Ammann AJ, Cowan MJ, Wara DW: Significance of a positive antinuclear antibody test in a pediatric population. Am J Dis Child 137: 1103 1106, 1983.Google Scholar
  111. 104.
    Velthuis PJ, Kater L, van der Tweel I, et al.: In vivo antinuclear antibody of the skin: diagnostic significance and association with selective antinuclear antibodies. Ann Rheum Dis 49: 163–167, 1990.CrossRefPubMedGoogle Scholar
  112. 105.
    Appel GB, Silva FG, Pirani CL, et al.: Renal involvement in systemic lupus erythematosus. Medicine 57: 371–410, 1978.CrossRefPubMedGoogle Scholar
  113. 106.
    Libit SA, Burke M, Michael A, et al.: Extramembranous glomerulonephritis in childhood: relationship to systemic lupus erythematosus. J Pediatr 88: 394–402, 1976.CrossRefPubMedGoogle Scholar
  114. 107.
    Morris RJ, Guggenheim SJ, McIntosh RM, et al.: Simultaneous immunologic studies of skin and kidney in systemic lupus erythematosus. Arthritis Rheum 22: 864–870, 1979.CrossRefPubMedGoogle Scholar
  115. 108.
    Singh AK, Rao KPP, Kizer J, Lazarchick J: Lupus anticoagulants in children. Ann Clin Lab Sci 18: 384–387, 1988.PubMedGoogle Scholar
  116. 109.
    Myones BL, Anderson BD, Rivas-Chacon RF, Mercer WD: Anti-phospholipid antibodies in juvenile rheumatoid arthritis (JRA). Arthritis Rheum 33: S93, 1990.Google Scholar
  117. a.Luchi ME, Asherson RA, Lahita RG: Primary idiopathic pulmonary hypertension complicated by pulmonary arterial thrombosis. Arthritis Rheum 35: 700705, 1992.Google Scholar
  118. 110.
    Rider LG, Clarke WR, Rutledge J: Pulmonary hypertension in a seventeenyear-old boy. J Pediatr 120: 149–159, 1992.CrossRefPubMedGoogle Scholar
  119. a.Asherson RA, Hughes CRV: Recurrent deep vein thrombosis and Addison’s disease in “primary” antiphospholipid syndrome. J Rheumatol 16: 378–380, 1989.Google Scholar
  120. b.Carette S, Jobin F: Acute adrenal insufficiency as a manifestation of the anticardiolipin syndrome? Ann Rheum Dis 48: 430–431, 1989.CrossRefGoogle Scholar
  121. 111.
    Weinstein C, Miller MH, Axtens R, et al.: Livedo reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus. Arch Dermatol 123: 596–600, 1987.CrossRefPubMedGoogle Scholar
  122. 112.
    Kalunian KC, Peter JB, Middlekauff HR, et al.: Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med 85: 602–608, 1988.CrossRefPubMedGoogle Scholar
  123. 113.
    Harris EN, Phil M, Asherson RA, et al.: Antiphospholipid antibodiesautoantibodies with a difference. Ann Rev Med 39: 261–271, 1988.CrossRefPubMedGoogle Scholar
  124. 114.
    Love PE, Santoro SA: Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 112: 682–698, 1990.CrossRefPubMedGoogle Scholar
  125. 115.
    Lockshin MD, Durzin ML, Goei S, et al.: Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N EnglJ Med 313:152–156, 1985 (see also correspondence p. 1350–1351).Google Scholar
  126. 116.
    Branch DW, Scott JR, Kochenour NK, Hershoold E: Obstetric complications associated with the lupus anticoagulant. N Engl J Med 313:1322–1326, 1985 (see also Editorial p. 1348–1350).Google Scholar
  127. 117.
    Danao-Camara T, Clough JD: Anticardiolipin antibodies in systemic lupus erythematosus. Clev Clin J Med 56: 525–528, 1989.Google Scholar
  128. 118.
    Pope JM, Canny CB, Bell DA: Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. Am J Med 90: 299–309, 1991.PubMedGoogle Scholar
  129. a.Viard J-P, Amoura Z, Bach J-F: Association of anti-ß2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 93: 181–186, 1992.CrossRefGoogle Scholar
  130. 119.
    Bernstein ML, Salusinsky-Sternback M, Bellefleur M, et al.: Thrombotic and hemorrhagic complications in children with the lupus anticoagulant. Am J Dis Child 138:1132–1135, 1984 (see also Editorial p. 1098 ).Google Scholar
  131. 120.
    Case records of the Massachusetts General Hospital. Case 11–1990. N Engl J Med 322: 754–769, 1990.CrossRefGoogle Scholar
  132. 121.
    Ryan BR, Arkel Y, Walters TR, et al.: Acquired symptomatic inhibitors of plasma clotting factors in nonhemphilic children. Am J Ped Hematol/Oncol 8: 144–148, 1986.Google Scholar
  133. 122.
    Simel DL, St. Clair EW, Adams J, Greenberg CS: Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulanthypoprothrombinemia syndrome. Am J Med 83: 563–566, 1987.CrossRefPubMedGoogle Scholar
  134. 123.
    Ordi J, Vilardel M, Oristrell J, et al.: Bleeding in patients with lupus anticoagulant. Lancet 2: 868–869, 1984.CrossRefPubMedGoogle Scholar
  135. 124.
    Brentjens JR, Andres GA: The pathogenesis of extrarenal lesions in systemic lupus erythematosus. Arthritis Rheum 25: 880–886, 1982.CrossRefPubMedGoogle Scholar
  136. 125.
    Mahajan SK, Ordonez NG, Feitelson PJ, et al.: Lupus nephropathy without clinical renal involvement. Medicine 56: 493–501, 1977.CrossRefPubMedGoogle Scholar
  137. 126.
    Woolf A, Croker B, Osofsky SG, et al.: Nephritis in children and young adults with systemic lupus erythematosus and normal urinary sediment. Pediatrics 64: 678–685, 1979.PubMedGoogle Scholar
  138. 127.
    Font J, Torras A, Cervera R, et al.: Silent renal disease in systemic lupus erythematosus. Clin Nephrol 27: 283–288, 1987.PubMedGoogle Scholar
  139. 128.
    Stamenkovic I, Favre H, Donath A, et al.: Renal biopsy in SLE irrespective of clinical findings: Long-term follow-up. Clin Nephrol 26: 109–115, 1986.PubMedGoogle Scholar
  140. 129.
    Baumal R, Farine M, Poucell S: Clinical significance of renal biopsies showing mixed mesengial and global proliferative lupus nephritis. Am J Kid Dis 10: 236240, 1987.Google Scholar
  141. 130.
    Baldwin DS, Gluck MC, Lowenstein J, et al.: Lupus nephritis. Clinical course as related to morphologic forms and their transition. Am J Med 62: 12–30, 1977.CrossRefPubMedGoogle Scholar
  142. 131.
    McCluskey RT: Lupus nephritis. In Sommers SC (ed.) Kidney Pathology Decennial 1966–1975. Appleton-Century-Crofts, New York, 1975, pp. 435–460.Google Scholar
  143. 132.
    McLaughlin J, Gladman DD, Urowitz MB, et al.: Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results. Arthritis Rheum 34: 1268–1273, 1991.CrossRefPubMedGoogle Scholar
  144. 133.
    Dumas R: Lupus Nephritis. Collaborative study by the French Society of Paediatric Nephrology. Arch Dis Child 60: 126–128, 1985.CrossRefPubMedGoogle Scholar
  145. 134.
    Tateno S, Kobayashi Y, Hidekazu S, Hiki Y: Study of lupus nephritis: its classification and the significance of subendothelial deposits. Q J Med 207: 31 1331, 1983.Google Scholar
  146. 135.
    Austin HA III, Muenz LR, Joyce KM, et al.: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 75: 382–391, 1983.CrossRefPubMedGoogle Scholar
  147. 136.
    BalowJE: Lupus as a renal disease. Hosp Pract pp. 129–146, October 15, 1988.Google Scholar
  148. 137.
    Nossent HC, Henzen-Logmans SC, Vroom TM, et al.: Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients. Arthritis Rheum 33: 970–977, 1990.CrossRefPubMedGoogle Scholar
  149. 138.
    Rush PH, Baumal R, Shore A, et al.: Correlation of renal histology with outcome in children with lupus nephritis. Kidney Int 29: 1066–1071, 1986.CrossRefPubMedGoogle Scholar
  150. 139.
    Ginzler EM, Bollet AJ, Friedman EA: The natural history and response to therapy of lupus nephritis. Ann Rev Med 31: 463–487, 1980.CrossRefPubMedGoogle Scholar
  151. 140.
    Hintz G, Acevedo-Vazquez E, Gutierrez-Espinosa G, Avelar-Garnica F: Renal vein thrombosis and inferior vena cava thrombosis in systemic lupus erythematosus. Frequency and risk factors. Arthritis Rheum 27: 539–544, 1984.CrossRefGoogle Scholar
  152. 141.
    Appel GB, Williams GS, Meltzer JI, et al.: Renal vein thrombosis, nephrotic syndrome, and systemic lupus erythematosus: An association in four cases. Ann Intern Med 85: 310–317, 1976.CrossRefPubMedGoogle Scholar
  153. 142.
    Donadio JV, Burgess JH, Holley KE: Membranous lupus nephropathy: A clinicopathologic study. Medicine 56: 527–536, 1977.CrossRefPubMedGoogle Scholar
  154. 143.
    Ross DI, Lubowitz R: Anticoagulation in renal vein thrombosis. Arch Intern Med 138: 1349–1351, 1978.CrossRefPubMedGoogle Scholar
  155. 144.
    Mailloux LU, Susin M, Stein HL, et al.: Nephrotic syndrome, membranous nephropathy, and renal vein thrombosis: Long-term follow-up. NY State J Med 78: 1873–1879, 1978.Google Scholar
  156. 145.
    Fries JF, Holman HR: Systemic Lupus Erythematosus: A Clinical Analysis. Saunders, Philadelphia, 1975.Google Scholar
  157. 146.
    Whiting-O’Keefe Q, Riccardi PJ, Henke JE, et al.: Recognition of information in renal biopsies of patients with lupus nephritis. Ann Intern Med 96: 723–727, 1982.CrossRefPubMedGoogle Scholar
  158. 147.
    Fries JF, Weyl S, Holman HR: Estimating prognosis in systemic lupus erythematosus. Am J Med 57: 561–565, 1974.CrossRefPubMedGoogle Scholar
  159. 148.
    Jacobs JC: Childhood onset systemic lupus erythematosus. NY State J Med 77: 2231–2233, 1977.Google Scholar
  160. 149.
    Ginzler EM, Diamond HS, Weiner M, et al.: A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 25: 601–611, 1982.CrossRefPubMedGoogle Scholar
  161. 150.
    Reichlin M: Significance of the Ro antigen system. J Clin Immunol 6: 339–348, 1986.CrossRefPubMedGoogle Scholar
  162. 151.
    Rubin LA, Urowitz MB, Gladman DD: Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Qtr J Med, New Series 55: 87–98, 1985.Google Scholar
  163. 152.
    Lehman TJA, McCurdy DK, Bernstein BH, et al.: Systemic lupus erythematosus in the first decade of life. Pediatrics 83: 235–239, 1989.PubMedGoogle Scholar
  164. 153.
    Hashimoto H, Tsuda H, Hirano T, et al.: Difference in clinical and immunological findings of systemic lupus erythematosus related to age. J Rheumatol 14: 497–501, 1987.PubMedGoogle Scholar
  165. 154.
    Celermajer DS, Thorner PS, Baumal R, et al.: Sex differences in childhood lupus nephritis. Am J Dis Child 138: 586–588, 1984.PubMedGoogle Scholar
  166. 155.
    Ward MM, Studenski S: Systemic lupus erythematosus in men: a multivariate analysis of gender differences in clinical manifestations. J Rheumatol 17: 220224, 1990.Google Scholar
  167. 156.
    Kaufman LD, Gomez-Reino JJ, Heinicke MH, Gorevic PD: Male lupus: analysis of the clinical and laboratory features of 52 patients, with a review of the literature. Semin Arthritis Rheum 18: 189–197, 1989.CrossRefPubMedGoogle Scholar
  168. 157.
    Tejani A, Nicastri AD, Chen C-K, et al.: Lupus nephritis in black and Hispanic children. Am J Dis Child 137: 481–483, 1983.PubMedGoogle Scholar
  169. 158.
    Ward MM, Studenski S: Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. Arch Intern Med 150: 849–853, 1990.CrossRefPubMedGoogle Scholar
  170. 159.
    Kasiske BL, Neylan III JF, Riggio RR, et al.: The effect of race on access and outcome in transplantation. N Engl J Med 324: 302–307, 1991.CrossRefPubMedGoogle Scholar
  171. 160.
    Callahan LF, Pincus T: Associations between clinical status questionnaire scores and formal education level in persons with systemic lupus erythematosus. Arthritis Rheum 33: 407–411, 1990.CrossRefPubMedGoogle Scholar
  172. 161.
    Urowitz MB, Bookman AAM, Koehler BE, et al.: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60: 221–225, 1976.CrossRefPubMedGoogle Scholar
  173. 162.
    Estes D, Christian CL: The natural history of systemic lupus erythematosus by prospective analysis. Medicine 50: 85–95, 1971.CrossRefPubMedGoogle Scholar
  174. 163.
    Karsh J, Klippel JH, Barlow JE, et al.: Mortality in lupus nephritis. Arthritis Rheum 22: 764–769, 1979.CrossRefPubMedGoogle Scholar
  175. 164.
    Swaak AJG, Nossent JC, Bronsveld W, et al.: Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 48: 447–454, 1989.CrossRefPubMedGoogle Scholar
  176. 165.
    Ginzler EM, Schorn K: Outcome and prognosis in systemic lupus erythematosus. Rheum Dis Clin North Am 14: 67–78, 1988.PubMedGoogle Scholar
  177. 166.
    Bresnihan B: Outcome and survival in systemic lupus erythematosus. Ann Rheum Dis 48: 443–445, 1989.CrossRefPubMedGoogle Scholar
  178. 167.
    Reveille JD, Bartolucci A, Alarcon GS: Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 33: 37–48, 1990.CrossRefPubMedGoogle Scholar
  179. 168.
    Helve T: Prevalence and mortality rates of systemic lupus erythematosus and causes of death in SLE patients in Finland. Scand J Rheum 14: 43–46, 1985.CrossRefPubMedGoogle Scholar
  180. 169.
    Jonsson H, Nived O, Sturfelt G: Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 68: 141–150, 1989.CrossRefPubMedGoogle Scholar
  181. 170.
    Harisdangkul V, Nilganuwonge S, Rockhold L: Cause of death in systemic lupus erythematosus: a pattern based on age at onset. S Med J 80: 1249–1253, 1987.CrossRefGoogle Scholar
  182. 171.
    Rosner S, Ginzler EM, Diamond HS, et al.: A multicenter study of outcome in systemic lupus erythematosus. II. Causes of Death. Arthritis Rheum 25: 61 2617, 1982.Google Scholar
  183. 172.
    Caeiro F, Michielson FMC, Bernstein R, et al.: Systemic lupus erythematosus in childhood. Ann Rheum Dis 40: 325–331, 1981.CrossRefPubMedGoogle Scholar
  184. 173.
    Glidden RS, Mantzouranis EC, Borel Y: Systemic lupus erythematosus in childhood: clinical manifestations and improved survival in fifty-five patients. Clin Immun Immunopathol 29: 196–210, 1983.CrossRefGoogle Scholar
  185. 174.
    Rosner S, Ginzler E, Diamond H, et al.: Causes of death in systemic lupus erythematosus, abstracted. Arthritis Rheum 23: 738, 1980.Google Scholar
  186. 175.
    Correria P, Cameron JS, Lian JD, et al.: Why do patients with lupus nephritis die? Br Med J 290: 126–131, 1985.CrossRefGoogle Scholar
  187. 176.
    Spiera H, Rothenberg RR: Myocardial infarction in four young patients with SLE. J Rheumatol 10: 464–466, 1983.PubMedGoogle Scholar
  188. 177.
    Jacobs JC: Lupus erythematosus with nephritis. Pediatrics 41: 369–370, 1968.Google Scholar
  189. 178.
    Ropes MW: Systemic Lupus Erythematosus. Harvard University Press, Cambridge, MA, 1976.Google Scholar
  190. 179.
    Heller CA, Schur PH: Serological and clinical remission in systemic lupus erythematosus. J Rheumatol 12: 916–918, 1985.PubMedGoogle Scholar
  191. 180.
    Swaak AJG, Nossent JC, Bronsveld W, et al.: Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 48: 455460, 1989.Google Scholar
  192. 181.
    Adelman DC, Wallace DJ, Klinenberg JR: Thirty-four-year delayed-onset lupus nephritis: a case report. Arthritis Rheum 30: 479–480, 1987.CrossRefPubMedGoogle Scholar
  193. 182.
    The Canadian Hydroxychloroquine Study Group: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324:150–154 (see also Editorial pp. 189–191 ), 1991.Google Scholar
  194. 182a.
    Bombardier C, Gladman DD, Urowitz MB, et al.: Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 35: 630–640, 1992.Google Scholar
  195. 183.
    Phadke K, Trachtman H, Nicastri A, et al.: Acute renal failure as the initial manifestation of systemic lupus erythematosus in children. J Pediatr 105: 38, 1984.CrossRefPubMedGoogle Scholar
  196. 184.
    Alverson DC, Chase HP: Systemic lupus erythematosus in childhood presenting as hyperlipoproteinemia. J Pediatr 91: 72–75, 1977.CrossRefPubMedGoogle Scholar
  197. 185.
    Falko JM, Williams JC, Harvey DG, et al.: Hyperlipoproteinemia and multifocal neurologic dysfunction in systemic lupus erythematosus. J Pediatr 95: 523529, 1979.Google Scholar
  198. 186.
    Tan EM, Cohen AS, Fries JF, et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277, 1982 (see also Correspondence, 26: 1055, 1983 ).Google Scholar
  199. 187.
    Ganczarczyk L, Urowitz MB, Gladman DD: Latent lupus. J Rheumatol 16: 475–478, 1989.Google Scholar
  200. 188.
    Greer JM, Panush RS: Incomplete lupus erythematosus. Arch Intern Med 149: 2473–2476, 1989.CrossRefPubMedGoogle Scholar
  201. 189.
    Passas CM, Wong RL, Peterson M, et al.: A comparison of the specificity of the 1971 and 1982 American Rheumatism Association criteria for classification of systemic lupus erythematosus. Arthritis Rheum 28: 620–623, 1985.CrossRefPubMedGoogle Scholar
  202. 190.
    Szer IS, Jacobs JC: Systemic lupus erythematosus of childhood. In Lahita RG (ed.) Systemic Lupus Erythematosus. 2nd ed, 1992. Churchill Livingstone, New York, pp. 397–418.Google Scholar
  203. 191.
    Mond CB, Peterson MGE, Rothfield NF: Correlation of anti-Ro antibody with photosensitivity rash in systemic lupus erythematosus patients. Arthritis Rheum 32: 202–204, 1989.CrossRefPubMedGoogle Scholar
  204. 192.
    Vaughn RY, Bailey JP Jr, Field RS, et al.: Diffuse nail dyschromia in black patients with systemic lupus erythematosus. J Rheumatol 17: 640–643, 1990.PubMedGoogle Scholar
  205. 193.
    Almeida L, Grossman M: Widespread dermatophyte infections that mimic collagen vascular disease. J Am Dermatol 23: 855–857, 1990.CrossRefGoogle Scholar
  206. 194.
    Franks AG Jr.: Identifying dermatologic manifestations of lupus erythematosus. J Musculoskel Med #4, pp. 59–75, #5 pp. 69–91, #7 pp. 39–57, 1988.Google Scholar
  207. 195.
    Kettler AH, Bean SF, Duffy JO, Gammon WR: Systemic lupus erythematosus presenting as a bullous eruption in a child. Arch Dermatol 124: 1083–1087, 1988.CrossRefPubMedGoogle Scholar
  208. 196.
    Olansky AJ, Briggaman RA, Gammon WR, et al.: Bullous systemic lupus erythematosus. J Am Acad Dermatol 7: 511–520, 1982.CrossRefPubMedGoogle Scholar
  209. 197.
    Hall RP, Lawlep TJ, Smith HR, et al.: Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 97: 165–170, 1982.CrossRefPubMedGoogle Scholar
  210. 198.
    Dotson AD, Raimer SS, Pursley TV, Tschen J: Systemic lupus erythematosus occurring in a patient with epidermolysis bullosa acquisita. Arch Dermatol 117: 422–426, 1981.CrossRefPubMedGoogle Scholar
  211. 199.
    Jacoby RA, Abraham AA: Bullous dermatosis and systemic lupus erythematosus in a 15-year-old boy. Arch Dermatol 115: 1094–1097, 1979.CrossRefPubMedGoogle Scholar
  212. 200.
    Helm KF, Peters MS: Immunodermatology update: The immunologically mediated vesiculobullous diseases. Mayo Clin Proc 66: 187–202, 1991.CrossRefPubMedGoogle Scholar
  213. 201.
    Ragsdale CG, Petty RE, Cassidy JT, et al.: The clinical progression of apparent juvenile rheumatoid arthritis to systemic lupus erythematosus. J Rheumatol 7: 50–55, 1980.PubMedGoogle Scholar
  214. 202.
    Saulsbury FT, Kesler RW, Kennaugh JM, et al.: Overlap syndrome of juvenile rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 9: 610612, 1982.Google Scholar
  215. 203.
    Panush RS, Edwards L, Longley S, Webster E: `Rhupus’ syndrome. Arch Intern Med 148: 1633–1636, 1988.CrossRefPubMedGoogle Scholar
  216. a.Kaplan D, Ginzler EM, Feldman J: Arthritis and hypertension in patients with systemic lupus erythematosus. Arthritis Rheum 35: 423–428, 1992.CrossRefGoogle Scholar
  217. b.Spronk PE, ter Borg EJ, Kallenberg CGM: Patients with systemic lupus erythematosus and Jaccoud’s arthropathy: a clinical subset with an increased C reactive protein response? Ann Rheum Dis 51: 358–361, 1992.CrossRefGoogle Scholar
  218. 204.
    Alarcon-Segovia D, Abud-Mendoza C, Diaz-Jouanen E: Deforming arthropathy of the hands in systemic lupus erythematosus. J Rheumatol 15: 65–69, 1988.PubMedGoogle Scholar
  219. 205.
    Villiaumey J, Arlet J, Avouac B, et al.: Diagnostic criteria and new etiologic events in the arthropathy of Jaccoud: a report of ten cases. Clin Rheumatol Pract 7: 156–174, 1986.Google Scholar
  220. 206.
    Martini A, Ravelli A, Viola S, Burgio RG: Systemic lupus erythematosus with Jaccoud’s arthropathy mimicking juvenile rheumatoid arthritis. Arthritis Rheum 30: 1062–1074, 1987.CrossRefPubMedGoogle Scholar
  221. 207.
    Coffman JD: Raynaud’s phenomenon. New York, Oxford University Press, 1989, pp. 1–186.Google Scholar
  222. 207a.
    Westphalen MA, McGrath MA, Kelly W, et al.: Kawasaki disease with severe peripheral ischemia: treatment with prostaglandin E1 infusion. J Pediatr 112: 431–433, 1988.CrossRefPubMedGoogle Scholar
  223. b.Yoshikawa T, Suzuki H, Kato H, Yano S: Effects of prostaglandin E1 on collagen diseases with high levels of circulating immune complexes. J Rheumatol 17: 1513–1514, 1990.Google Scholar
  224. 208.
    Schikler KN, Nagaraj HS, Hodge KM: Torsion of appendix epiploica and acute abdominal pain in systemic lupus erythematosus. Am J Dis Child 136: 748, 1982.PubMedGoogle Scholar
  225. 209.
    Zizic TM, Shulman LE, Stevens MB: Colonic perforations in systemic lupus erythematosus. Medicine 54: 411–426, 1975.CrossRefPubMedGoogle Scholar
  226. 210.
    Nadorra RL, Nakazato Y, Landing BH: Pathologic features of gastrointestinal tract lesions in childhood-onset systemic lupus erythematosus: study of 26 patients, with review of the literature. Ped Pathol 7: 245–259, 1987.CrossRefGoogle Scholar
  227. 211.
    Gladman DD, Ross T, Richardson B, Kulkarni S: Bowel involvement in systemic lupus erythematosus: Crohn’s disease or lupus vasculitis? Arthritis Rheum 28: 466–470, 1985.CrossRefPubMedGoogle Scholar
  228. 212.
    Reynolds JC, Inman RD, Kimberly RP, et al.: Acute pancreatitis in SLE: report of twenty cases and a review of the literature. Medicine 61: 25–32, 1982.CrossRefPubMedGoogle Scholar
  229. 213.
    Marino C, Lipstein-Kresch E: Pancreatitis in systemic lupus erythematosus. Arthritis Rheum 27: 118–119, 1984.CrossRefPubMedGoogle Scholar
  230. 214.
    Martini A, Notarangelo LD, Barberis L: Pancreatitis in systemic lupus. Arthritis Rheum 26: 1173, 1983.CrossRefPubMedGoogle Scholar
  231. 215.
    Goldberg BH, Bergstein JM: Acute respiratory distress in a child after steroid-induced pancreatitis. Pediatrics 61: 317–318, 1978.PubMedGoogle Scholar
  232. 216.
    Alverson DC, Chase HP: Systemic lupus erythematosus in childhood presenting as hyperlipoproteinemia. J Pediatr 91: 72–75, 1977.CrossRefPubMedGoogle Scholar
  233. 217.
    Lipsky PE, Hardin JA, Schour L, et al.: Spontaneous peritonitis and systemic lupus erythematosus. JAMA 232: 929–931, 1975.CrossRefPubMedGoogle Scholar
  234. 218.
    Hamdan JA, Ahmad MS, Sa’adi AR: Malacoplakia of the retroperitoneum in a girl with systemic lupus erythematosus. Pediatrics 70: 296–299, 1982.PubMedGoogle Scholar
  235. 219.
    Mor F, Beigel Y, Inbal A, et al.: Hepatic infarction in a patient with the lupus anticoagulant. Arthritis Rheum 32: 491–495, 1989.CrossRefPubMedGoogle Scholar
  236. 220.
    Averbuch M, Levo Y: Budd-Chiari syndrome as the major thrombotic complication of systemic lupus erythematosus with the lupus anticoagulant. Ann Rheum Dis 45: 435–437, 1986.CrossRefPubMedGoogle Scholar
  237. 221.
    Lloyd DD, Balfe JW, Barkin M, et al.: Systemic lupus erythematosus with signs of retroperitoneal fibrosis. J Pediatr 85: 226–228, 1974.CrossRefGoogle Scholar
  238. a.BuffDD: The etiology of retroperitoneal fibrosis. NYS J Med 91: 336–338, 1991.Google Scholar
  239. 222.
    Bitran J, McShane D, Ellman MH: Ascites as the major manifestation of systemic lupus erythematosus. Arthritis Rheum 19: 782–785, 1976.CrossRefPubMedGoogle Scholar
  240. 223.
    Kaklamanis P, Vayopoulos G, Stamatelos G, et al.: Chronic lupus peritonitis with ascites. Ann Rheum Dis 50: 176–177, 1991.CrossRefPubMedGoogle Scholar
  241. 224.
    Tsutsumi A, Sugiyama T, Matsumura R, et al.: Protein losing enteropathy associated with collagen disease. Ann Rheum Dis 50: 178–181, 1991.CrossRefPubMedGoogle Scholar
  242. 225.
    Perednia DA, Curosh NA: Lupus-associated protein-losing enteropathy. Arch Intern Med 150: 1806–1810, 1990.CrossRefPubMedGoogle Scholar
  243. 226.
    Tsukahara M, Matsuo K, Kojima H: Protein-losing enteropathy in a boy with systemic lupus erythematosus. J Pediatr 97: 778–780, 1980.CrossRefPubMedGoogle Scholar
  244. 227.
    Case records of the Massachusetts General Hospital (case no. 42–1979). N Engl J Med 301: 881–887, 1979.CrossRefGoogle Scholar
  245. 228.
    Rosenstein ED, Wieczorek R, Raphael BG, Agus B: Systemic lupus erythematosus and angioimmunoblastic lymphadenopathy: case report and review of the literature. Semin Arthritis Rheum 16: 146–151, 1986.CrossRefPubMedGoogle Scholar
  246. 229.
    Steinberg AD, Seldin MF, Jaffe ES, et al.: Angioimmunoblastic lymphadenopathy with dysproteinemia. Ann Intern Med 108: 575–584, 1988.CrossRefPubMedGoogle Scholar
  247. 230.
    Runyon BA, Labrecque DR, Anuras S: The spectrum of liver disease in systemic lupus erythematosus. Am J Med 69: 187–194, 1980.CrossRefPubMedGoogle Scholar
  248. 231.
    Maggiore G, Porta G, Bernard O, et al.: Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 116: 280–281, 1990.CrossRefPubMedGoogle Scholar
  249. 232.
    Budman JR, Steinberg AD: Hematologic aspects of systemic lupus erythematosus. An Intern Med 86: 220–229, 1977.CrossRefGoogle Scholar
  250. 233.
    Schreiber AD: Immunohematology. JAMA 248: 1380–1385, 1982.CrossRefPubMedGoogle Scholar
  251. 234.
    Bailey FA, Lilly M, Bertoli LF, Ball GV: An antibody that inhibits in vitro bone marrow proliferation in a patient with systemic lupus erythematosus and aplastic anemia. Arthritis Rheum 32: 901–905, 1989.PubMedGoogle Scholar
  252. 235.
    Heck LW, Alarcon GS, Ball GV, et al.: Pure red cell aplasia and protein-losing enteropathy in a patient with systemic lupus erythematosus. Arthritis Rheum 28: 1059–1061, 1985.CrossRefPubMedGoogle Scholar
  253. 235a.
    Wong K-F, Chan JKC: Reactive hemophagocytic syndrome-A clinicopathologic study of 40 patients in an oriental population. Am J Med 93: 177–180, 1992.CrossRefPubMedGoogle Scholar
  254. 236.
    Eschbach JW, Kelly MR, Haley NR, et al.: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321: 158–163, 1989.CrossRefPubMedGoogle Scholar
  255. 237.
    McGuire WA, Yang HH, Bruno E, et al.: Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med 317: 1004–1008, 1987.CrossRefPubMedGoogle Scholar
  256. 238.
    Winkler A, Jackson RW, Kay DS, et al.: High-dose intravenous cyclophosphamide treatment of systemic lupus erythematosus-associated aplastic anemia. Arthritis Rheum 31: 693–694, 1988.CrossRefPubMedGoogle Scholar
  257. 239.
    Brooks Jr BJ, Broxmeyter HE, Bryan CF, Leech SH: Serum inhibitor in systemic lupus erythematosus associated with aplastic anemia. Arch Intern Med 144:1474–1477; 1984.Google Scholar
  258. 240.
    Fitchen JJ, Cline MJ, Saxon A, Golde DW: Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosus. Recovery after exchange plasmapheresis. Am J Med 66: 537–542, 1979.CrossRefPubMedGoogle Scholar
  259. 241.
    Stricker RB, Shuman MA: Aplastic anemia complicating systemic lupus erythematosus: response to androgens in two patients. Am J Hematol 17: 193–201, 1984.CrossRefPubMedGoogle Scholar
  260. 242.
    Cines DB, Passero F, Guerry IV D, et al.: Granulocyte-associated IgG in neutropenic disorders. Blood 59: 124–132, 1982.PubMedGoogle Scholar
  261. 243.
    Wetzler M, Talpaz M, Kleinerman ES, et al.: A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med 89: 663–672, 1990.CrossRefPubMedGoogle Scholar
  262. 243a.
    Wetzler M, Talpaz M, Kellagher MJ, et al.: Myelokathexis: Normalization of neutrophil counts and morphology by GM-CSF. JAMA 267: 2179–80, 1992.Google Scholar
  263. 244.
    Karpatkin S: Autoimmune thrombocytopenic purpura. Clinical Aspects Auto-immunity, 2: 21–37, 1988.Google Scholar
  264. 245.
    Imbach PI, Tani P, Berchtold W, et al.: Different forms of chronic childhood thrombocytopenic purpura defined by antiplatelet autoantibodies. J Pediatr 118: 535–539, 1991.CrossRefPubMedGoogle Scholar
  265. 246.
    Maier WP, Gordon DS, Howard RF, et al.: Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum 33:1233–1239, 1990 (see also correspondence 34: 787–789, 1991 ).Google Scholar
  266. 246a.
    Andrew M, Blanchette VS, Adams M, et al.: A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D. J Pediatr 120: 522–527, 1992.Google Scholar
  267. 247.
    West SG, Johnson SC: Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 108: 703706, 1988.Google Scholar
  268. 248.
    Ahn YS, Rocha R, Mylvaganam R, et al.: Long-term Danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med 111: 723–729, 1989.CrossRefPubMedGoogle Scholar
  269. 249.
    Marino C, Cook P: Danazol for lupus thrombocytopenia. Arch Intern Med 145: 2251–2252, 1985.CrossRefPubMedGoogle Scholar
  270. 250.
    Ahn YS, Mylvaganam R, Garcia RO, et al.: Low-dose Danazol therapy in idiopathic thrombocytopenic purpura. Ann Intern Med 107: 177–181, 1987.CrossRefPubMedGoogle Scholar
  271. 251.
    Schreiber AD, Chien P, Tomaski A, Cines DB: Effect of Danazol in immune thrombocytopenic purpura. N Engl J Med 316: 503–508, 1987.CrossRefPubMedGoogle Scholar
  272. 252.
    Boumpas DT, Barez S, Klippel JH, Balow JE: Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 112: 674–677, 1990.CrossRefPubMedGoogle Scholar
  273. 253.
    Rivero SJ, Alger M, Alarcon-Segovia D: Splenectomy for hemocytopenia in systemic lupus erythematosus. Arch Intern Med 139: 773–776, 1979.CrossRefPubMedGoogle Scholar
  274. 254.
    Gruenberg JC, VanSlyck EJ, Abraham JP: Splenectomy in systemic lupus erythematosis. Am Surgeon 52: 336–370, 1986.Google Scholar
  275. 255.
    Gladman DD, Urowitz MB, Tozman EC, Glynn MFX: Haemostatic abnormalities in systemic lupus erythematosus. Q J Med 207: 424–433, 1983.Google Scholar
  276. 256.
    Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE: Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 2: 765–768, 1984.CrossRefPubMedGoogle Scholar
  277. 257.
    Peck B, Hoffman GS, Franck WA: Thrombophlebitis in systemic lupus erythematosus. JAMA 240: 1728–1730, 1978.CrossRefPubMedGoogle Scholar
  278. 258.
    Cosgriff TM, Martin BA: Low functional and high antigenic antithrombin III level in a patient with lupus anticoagulant and recurrent thrombosis. Arthritis Rheum 24: 94–96, 1981.CrossRefPubMedGoogle Scholar
  279. 259.
    St. Clair W, Jones B, Rogers JS, et al.: Deep venous thrombosis and a circulating anticoagulant in systemic lupus erythematosus. Am J Dis Child 135: 230–232, 1981.Google Scholar
  280. 260.
    Boey ML, Loizou S, Colaco CB, et al.: Antithrombin III in systemic lupus erythematosus. Clin Exp Rheumatol 2: 53–56, 1984.PubMedGoogle Scholar
  281. 261.
    Kerr LD, Spiera H, Aledort LN: Acute disseminated intravascular coagulation as a complication of systemic lupus erythematosus. NYS J Med 87: 181–183, 1987.Google Scholar
  282. 262.
    Pui C-H, Wilimas J, Wang W: Evans syndrome in childhood. J Pediatr 97: 754758, 1980.Google Scholar
  283. 263.
    Favre H, Chatelanat F, Miescher P: Autoimmune hematologic diseases associated with infraclinical systemic lupus erythematosus in four patients: A human equivalent of the NZB mice. Am J Med 66: 91–95, 1979.CrossRefPubMedGoogle Scholar
  284. 264.
    Miller BA, Beardsley DS: Autoimmune pancytopenia of childhood associated with multisystem disease manifestations. J Pediatr 103: 877–881, 1983.CrossRefPubMedGoogle Scholar
  285. 265.
    Lavalle C, Hurtado R, Quezada JJ, et al.: Hemocytopenia as initial manifestation of systemic lupus erythematosus. Prognostic significance. Clin Rheumatol 2: 227–232, 1983.CrossRefPubMedGoogle Scholar
  286. 266.
    Miller MH, Urowitz MB, Gladman DD: The significance of thrombocytopenia in systemic lupus erythematosus. Arthritis Rheum 26: 1181–1186, 1983.CrossRefPubMedGoogle Scholar
  287. 267.
    White LE, Reeves JD: Polyarthritis and positive LE preparation in sickle hemoglobinopathies: A report of two cases. J Pediatr 95: 1003–1004, 1979.CrossRefPubMedGoogle Scholar
  288. 268.
    Young GAR, Vincent PC: Infectious mononucleosis and systemic lupus erythematosus. Lancet 1: 971–972, 1982.CrossRefPubMedGoogle Scholar
  289. 269.
    Hendry BM, Longmore JM: Systemic lupus erythematosus presenting as infectious mononucleosis with a false positive monospot test. Lancet 1: 455, 1982.CrossRefPubMedGoogle Scholar
  290. 270.
    Wu KK: Microvascular thrombosis: patholophysiology and new strategies. Hosp Pract 20:47–54, May 15, 1985.Google Scholar
  291. 271.
    Jain R, Chartash E, Furie R: Systemic lupus erythematosus complicated by thrombotic microangiopathy. Arthritis Rheum 34: S93, 1991.Google Scholar
  292. 272.
    Wallace DJ, Podell T, Weiner J, et al.: Systemic lupus erythematosus-survival patterns. Experience with 609 patients. JAMA 245: 934–938, 1981.CrossRefPubMedGoogle Scholar
  293. 273.
    Wallace DJ, Pistiner M, Klinenberg JR, et al.: 464 patients with idiopathic SLE: natural course, treatment and causes of death. Arthritis Rheum 33S: 130, 1990.Google Scholar
  294. 274.
    Elseviers MM, Verpooten GA, De Broe ME, DeBacker GG: Interpretation of creatinine clearance. Lancet 1: 457, 1987.CrossRefPubMedGoogle Scholar
  295. 275.
    Roubenoff R, Drew H, Moyer M, et al.: Oral cimetidine improves the accuracy and precision of creatinine clearance in lupus nephritis. Ann Intern Med 113: 501, 1990.CrossRefPubMedGoogle Scholar
  296. 276.
    Ratain JS, Petri M, Hochberg MC, Hellmann DB: Accuracy of creatinine clearance in measuring glomerular filtration rate in patients with systemic lupus erythematosus without clinical evidence of renal disease. Arthritis Rheum 33: 277–280, 1990.CrossRefPubMedGoogle Scholar
  297. 277.
    Cathcart ES, Scheinberg MA, Idelson BA: Beneficial effects of methylprednisone “pulse” therapy in diffuse proliferative lupus nephritis. Lancet 1: 163–166, 1976.CrossRefPubMedGoogle Scholar
  298. 278.
    Cole BR, Brocklebank JT, Kienstra RA, et al.: “Pulse” methylprednisolone therapy in the treatment of severe glomerulonephritis. J Pediatr 88: 307–314, 1976.CrossRefPubMedGoogle Scholar
  299. 279.
    Garrett R, Paulus H: Complications of intravenous methylprednisone pulse therapy, abstracted. Arthritis Rheum 23: 677, 1980.Google Scholar
  300. 280.
    Moore WS, Guggenheim SJ, Anderson RJ: Diffuse proliferative lupus glomerulonephritis: Recovery from prolonged renal failure. JAMA 244: 63–65, 1980.CrossRefPubMedGoogle Scholar
  301. 281.
    Edworthy SM, Bloch DA, McShane DJ, et al.: A “state model” of renal function in systemic lupus erythematosus: its value in the prediction of outcome in 292 patients. J Rheumatol 16: 29–35, 1989.PubMedGoogle Scholar
  302. 282.
    Kimberly RP, Lockshin MD, Sherman RL, et al.: Reversible “end-stage” lupus nephritis. Analysis of patients able to discontinue dialysis. Am J Med 74: 36 1368, 1983.Google Scholar
  303. 283.
    Nossent HC, Swaak TJG, Berden JHM, Dutch Working Party on SLE: Systemic lupus erythematosus after renal transplantation: patient and graft survival and disease activity. Ann Intern Med 114: 183–188, 1991.CrossRefPubMedGoogle Scholar
  304. 284.
    Nossent HC, Swaak TJG, Berden JHM, et al.: Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Am J Med 89: 169–174, 1990.CrossRefPubMedGoogle Scholar
  305. Lee FO, Quismorio EP Jr. Troum OM, et al.: Mechanisms of hyperkalemia in systemic lupus erythematosus. Ann Intern Med 148:397–401, 1988.Google Scholar
  306. 286.
    Ostrov BE, Min W, Eichenfield AH, et al.: Hypertension in children with systemic lupus erythematosus. Semin Arthritis Rheum 19: 90–98, 1989.CrossRefPubMedGoogle Scholar
  307. 287.
    Laragh JH: Hypertension. Drug Therapy 10: 71–88, January 1980.Google Scholar
  308. 288.
    McCurdy DK, Lehman TJA, Bernstein B et al.: Lupus nephritis: Prognostic factors in children. Pediatrics 89: 240–249, 1992.PubMedGoogle Scholar
  309. a.Seleznick MJ, Fries JF: Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum 21: 73–80, 1991.CrossRefGoogle Scholar
  310. 289.
    Dresner JG, Dysart NK, Michael AF, et al.: Central nervous system (CNS) lupus erythematosus (LE) in children, abstracted. Pediatr Res 12: 551, 1978.CrossRefGoogle Scholar
  311. 290.
    Weber MA: Editorials: Immediate treatment of severe hypertension. Widening the options. Arch Intern Med 149: 2635–2636, 1989.CrossRefPubMedGoogle Scholar
  312. 291.
    Sturgill BC, Shearlock KT: Membranous glomerulopathy and nephrotic syndrome after captopril therapy. JAMA 250: 2343–2345, 1983.CrossRefPubMedGoogle Scholar
  313. 292.
    Messerli FH (Editor): Calcium antagonists: current use and future implications: proceedings of a symposium. Am J Med 90(5A):1–53S, 1991.Google Scholar
  314. a.Epstein M: Calcium antagonists and renal protection. Arch Intern Med 152: 1573–1584, 1992.CrossRefGoogle Scholar
  315. 293.
    KlinkhoffAV, Beattie CW, Chalmers A: Retinopathy in systemic lupus erythematosus: relationship to disease activity. Arthritis Rheum 29: 1152–1156, 1986.CrossRefGoogle Scholar
  316. 294.
    Stafford-Brady FJ, Urowitz MB, Cladman DD, Easterbrook M: Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum 31: 1105–1110, 1988.CrossRefPubMedGoogle Scholar
  317. 295.
    Silverman M, Lubeck MJ, Briney EG: Central retinal vein occlusion complicating systemic lupus erythematosus. Arthritis Rheum 21: 839–843, 1978.CrossRefPubMedGoogle Scholar
  318. 296.
    Kraus A, Cervantes G, Barojas E, Alarcon Segovia D: Retinal vasculitis in mixed connective tissue disease. A fluorangiographic study. J Rheumatol 12: 1122–1124, 1985.PubMedGoogle Scholar
  319. 297.
    Smith CA, Pinals RS: Optic neuritis in systemic lupus erythematosus. J Rheumatol 9: 963–966, 1982.PubMedGoogle Scholar
  320. 298.
    Kenik JG, Krohn K, Kelly RB, et al.: Transverse myelitis and optic neuritis in systemic lupus erythematosus: a case report with magnetic resonance imaging findings. Arthritis Rheum 30: 947–950, 1987.CrossRefPubMedGoogle Scholar
  321. 299.
    Tsokos GC, Tsokos M, le Riche NGH, Klippel JH: A clinical and pathologic study of cerebrovascular disease in patients with systemic lupus erythematosus. Semin Arthritis Rheum 16: 70–78, 1986.CrossRefPubMedGoogle Scholar
  322. 300.
    Omdal R, Mellgren SI, Husby G: Clinical neuropsychiatric and neuromuscular manifestations in systemic lupus erythematosus. Scand J Rheumatol 17: 113117, 1988.Google Scholar
  323. 301.
    Yancey CL, Doughty RA, Athreya BH: Central nervous system involvement in childhood systemic lupus erythematosus. Arthritis Rheum 24: 1389–1395, 1981.CrossRefPubMedGoogle Scholar
  324. 302.
    Vermess M, Bernstein RM, Bydder GM, et al.: Nuclear magnetic resonance (NMR) imaging of the brain in systemic lupus erythematosus. J Comput Assist Tomogr 7: 461–467, 1983.CrossRefPubMedGoogle Scholar
  325. 302a.
    Hay EM, Black D, Huddy A, et al.: Psychiatric disorder and cognitive impair- ment in systemic lupus erythematosus. Arthritis Rheum 35: 411–416, 1992.Google Scholar
  326. 303.
    King J, Aukett A, Smith MF, et al.: Cerebral systemic lupus erythematosus. Arch Dis Child 63: 968–970, 1988.CrossRefPubMedGoogle Scholar
  327. 304.
    Winfield JB, Brunner CM, Koffler D: Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. Arthritis Rheum 21: 289–294, 1978.CrossRefPubMedGoogle Scholar
  328. 305.
    Hopkins P, Belmont HM, Buyon J, et al.: Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 31: 632–641, 1988.CrossRefPubMedGoogle Scholar
  329. 306.
    Johnson RT, Richardson EP: The neurological manifestations of systemic lupus erythematosus. Medicine 47: 337–369, 1968.CrossRefPubMedGoogle Scholar
  330. 307.
    Gershwin ME, Hyman LR, Steinberg AD: The choroid plexus in CNS involvement of systemic lupus erythematosus. J Pediatr 87: 588–590, 1975.CrossRefPubMedGoogle Scholar
  331. 308.
    Zvaifler NJ, Bluestein HG: The pathogenesis of central nervous system manifestations of systemic lupus erytematosus. Arthritis Rheum 25: 862–866, 1982.CrossRefPubMedGoogle Scholar
  332. 309.
    Bonfa E, Golombek SJ, Kaufman LD, et al.: Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 317:265–311, 1987 (see also editorial p. 309–311).Google Scholar
  333. 310.
    Schneebaum AB, Singleton JD, West SG, et al.: Association of psychiatric manifestations with antibodies to ribosmal P proteins in systemic lupus erythematosus. Am J Med 90: 54–62, 1991.CrossRefPubMedGoogle Scholar
  334. 311.
    Shergy WJ, Kredich DW, Pisetsky DS: The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus. J Rheumatol 15: 1389–1394, 1988.PubMedGoogle Scholar
  335. 312.
    Nossent JC, Hovestadt A, Schonfeld DHW, et al.: Single-photon-emission computed tomography of the brain in the evaluation of cerebral lupus. Arthritis Rheum 34: 1397–1403, 1991.CrossRefPubMedGoogle Scholar
  336. 313.
    Pinching AJ, Travers RL, Hughes GRV: Oxygen-15 brain scanning for detection of cerebral involvement in systemic lupus erythematosus. Lancet 1: 888890, 1978.Google Scholar
  337. 314.
    Kushner MJ, Chawluk J, Fazekas F, et al.: Cerebral blood flow in systemic lupus erythematosus with or without cerebral complications. Neurology 37: 1596–1598, 1987.CrossRefPubMedGoogle Scholar
  338. 315.
    Bilaniuk LT, Patel S, Zimmerman RA: Computed tomography of systemic lupus erythematosus. Radiology 124: 119–121, 1977.PubMedGoogle Scholar
  339. 316.
    Bell CL, Partington C, Robbins M, et al.: Magnetic resonance imaging of central nervous system lesions in patients with lupus erythematosus. Correlation with clinical remission and antineurofilament and anticardiolipin antibody titers. Arthritis Rheum 34: 432–441, 1991.CrossRefPubMedGoogle Scholar
  340. 317.
    Nordstrom DM, West SG, Andersen PA: Basal ganglia calcifications in central nervous system lupus erythematosus. Arthritis Rheum 28: 1412–1416, 1985.CrossRefPubMedGoogle Scholar
  341. 318.
    Yokota S, Mori T, Kosuge K, et al.: (Abstract) Basal ganglia calcification in two children with systemic lupus erythematosus and neuropsychiatric manifestations. Ryumachi 25: 121–122, 1985.Google Scholar
  342. 319.
    Brandt KD, Lessell S: Migrainous phenomena in systemic lupus erythematosus. Arthritis Rheum 21: 7–16, 1978.CrossRefPubMedGoogle Scholar
  343. 320.
    Carlow TJ, Glaser JS: Pseudotumor cerebri in systemic lupus erythematosus. JAMA 228: 197–200, 1974.CrossRefPubMedGoogle Scholar
  344. 321.
    Shoenfeld Y, Livni E, Shaklai M, et al.: Sensitization to ibuprofen in systemic lupus erythematosus. JAMA 244: 547–548, 1980.CrossRefPubMedGoogle Scholar
  345. 322.
    Kassan SS, Lockshin MD: Central nervous system lupus erythematosus. Arthritis Rheum 22: 1382–1385, 1979.CrossRefPubMedGoogle Scholar
  346. 323.
    Lehman TJA, Bernstein B, Hanson V, et al.: Meningococcal infection complicating systemic lupus erythematosus. J Pediatr 99: 94–96, 1981.CrossRefPubMedGoogle Scholar
  347. 324.
    Jabs DA, Miller NR, Newman SA, et al.: Optic neuropathy in systemic lupus erythematosus. Arch Ophthalmol 104: 564–568, 1986.CrossRefPubMedGoogle Scholar
  348. 325.
    Sharfstein SS, Sack DS, Fauci AS: Relationship between alternate-day corticosteroid therapy and behavioral abnormalities. JAMA 248: 2987–2989, 1982.CrossRefPubMedGoogle Scholar
  349. a.Dungan DD, Jay MS: Stroke in an early adolescent with systemic lupus erythematosus and coexistent antiphospholipid antibodies. Pediatrics 90: 96–99, 1992.Google Scholar
  350. 326.
    Cronin ME, Biswas RM, Van der Straeton C, et al.: IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated clinical syndromes. J Rheumatol 15: 795–798, 1988.PubMedGoogle Scholar
  351. 327.
    Asherson RA, Lubbe WF: Editorial: Cerebral and valve lesions in SLE: association with antiphospholipid antibodies. J Rheumatol 15: 539–543, 1988.PubMedGoogle Scholar
  352. 328.
    Harris EN, Gharvai AE, Asherson RA, et al.: Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol 2: 4751, 1984.Google Scholar
  353. 329.
    Asherson RA, Derksen RHWM, Harris EN, et al.: Chorea in systemic lupus erythematosus and “lupus-like” disease: association with antiphospholipid antibodies. Semin Arthritis Rheum 16: 253–259, 1987.CrossRefPubMedGoogle Scholar
  354. 330.
    Lusins JO, Szilagyi PA: Clinical features of chorea associated with systemic lupus erythematosus. Am J Med 58: 857–861, 1975.CrossRefPubMedGoogle Scholar
  355. 331.
    Groothius JR, Groothius DR, Mukhopadhyay D, et al.: Lupus-associated chorea in childhood. Am J Dis Child 131: 1131–1134, 1977.Google Scholar
  356. 332.
    Herd JK, Medhi M, Uzendoski DM, et al.: Chorea associated with systemic lupus erythematosus: Report of two cases and review of the literature. Pediatrics 61: 308–315, 1978.PubMedGoogle Scholar
  357. 333.
    Andrianakos AA, Duffy J, Suzuki M, et al.: Transverse myelopathy in systemic lupus erythematosus: Report of three cases and review of the literature. Ann Intern Med 83: 616–624, 1975.CrossRefPubMedGoogle Scholar
  358. 334.
    de Brum-Fernandes AJ, de F. Lucena-Fernandes M, Levy-Neto M, Cossermelli W: Myelitis in systemic lupus erythematosus. Arthritis Rheum 30: 238–239, 1987.CrossRefPubMedGoogle Scholar
  359. 335.
    Chang R, Quismorio FP Jr.: Transverse myelopathy in systemic lupus erythematosus (SLE). Arthritis Rheum 33S: 102, 1990.CrossRefGoogle Scholar
  360. 336.
    Guthrie JA, Turney JH: Plasma exchange for cerebral lupus erythematosus. Lancet 1: 506–507, 1987.CrossRefPubMedGoogle Scholar
  361. 337.
    Smith GM, Leyland MJ: Plasma exchange for cerebral lupus erythematosus. Lancet 1: 103, 1987.CrossRefGoogle Scholar
  362. 338.
    Warren RW, Kredich DW: Transverse myelitis and acute central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum 27: 1058 1060, 1984.Google Scholar
  363. 339.
    Propper DJ, Bucknall RC: Acute transverse myelopathy complicating systemic lupus erythematosus. Ann Rheum Dis 48: 512–515, 1989.CrossRefPubMedGoogle Scholar
  364. 340.
    Sloan JB, Berk MA, Gebel HM, Fretzin DF: Multiple sclerosis and systemic lupus erythematosus. Arch Intern Med 147: 1317–1320, 1987.CrossRefPubMedGoogle Scholar
  365. 341.
    Kaplan RE, Springate JE, Feld LG, Cohen ME: Pseudotumor cerebri associated with cerebral venous sinus thrombosis, internal jugular vein thrombosis, and systemic lupus erythematosus. J Pediatr 107: 266–268, 1985.PubMedGoogle Scholar
  366. 342.
    Li EK, Ho PCP: Pseudotumor cerebri in systemic lupus erythematosus. J Rheumatol 16: 113–116, 1989.PubMedGoogle Scholar
  367. 343.
    Wasner CK: Ibuprofen, meningitis, and systemic lupus erythematosus. J Rheumatol 5: 162–164, 1978.PubMedGoogle Scholar
  368. 344.
    Agus B, Nayar S, Patel DJ, McGrath M: Inappropriate secretion of ADH in a patient with systemic lupus erythematosus. Arthritis Rheum 26:237–238, 1983 (see also correspondence p. 1055 ).Google Scholar
  369. 345.
    Scheinberg L: Polyneuritis in systemic lupus erythematosus. Review of the literature and report of a case. N Engl J Med 255: 416–421, 1956.CrossRefPubMedGoogle Scholar
  370. 346.
    van Doom PA, Vermeulen M, Brand A, et al.: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 48: 217–220, 1991.CrossRefGoogle Scholar
  371. 347.
    Winfield JB, Brunner CM, Koffler D: Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. Arthritis Rheum 21: 289–294, 1978.CrossRefPubMedGoogle Scholar
  372. 348.
    Englert HJ, Loizou S, Derue GGM, et al.: Clinical and immunologic features of livedo reticularis in lupus: a case-control study. Am J Med 87: 408–410, 1989.CrossRefPubMedGoogle Scholar
  373. 349.
    Strauer BE, Brune I, Schenk H, et al.: Lupus cardiomyopathy: Cardiac mechanics, hemodynamics, and coronary blood flow in uncomplicated systemic lupus erythematosus. Am Heart J 92: 715–722, 1976.CrossRefPubMedGoogle Scholar
  374. 350.
    Bulkley BH, Roberts EC: The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. Am J Med 58: 243–264, 1975.CrossRefPubMedGoogle Scholar
  375. 351.
    Mandell BF: Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum 17: 126–141, 1987.CrossRefPubMedGoogle Scholar
  376. 352.
    Crozier IG, Li E, Milne MJ, Nicholls MG: Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol 65: 1145 1148, 1990.Google Scholar
  377. 353.
    Lehman TJA, Palmeri ST, Hastings C, et al.: Bacterial endocarditis complicating systemic lupus erythematosus. J Rheumatol 10: 655–658, 1983.PubMedGoogle Scholar
  378. 354.
    Averbuch M, Bojko A, Levo Y: Cardiac tamponade in the early postpartum period as the presenting and predominant manifestation of systemic lupus erythematosus. J Rheumatol 13: 444 445, 1986.Google Scholar
  379. 355.
    Alpert MA, Goldberg SH, Singsen BH, et al.: Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 68: 1182–1193, 1983.CrossRefPubMedGoogle Scholar
  380. 356.
    Holloway JD, Garcia W, Espinoza LR: Cardiac tamponade in a healthy young woman. Hosp Pract 23:128–134, July 15, 1987.Google Scholar
  381. 357.
    Greenberg JH, Lutcher CL: Drug-induced systemic lupus erythematosus: a case with life-threatening pericardial tamponade. JAMA 222: 191–193, 1972.CrossRefPubMedGoogle Scholar
  382. 358.
    Carey RM, Coleman M, Feder A: Pericardial tamponade: a major presenting manifestation of hydralazine-induced lupus syndrome. Am J Med 54: 84–87, 1973.CrossRefPubMedGoogle Scholar
  383. 359.
    Jacobson EJ, Reza JJ: Constrictive pericarditis in systemic lupus erythematosus; demonstration of immunoglobulins in the pericardium. Arthritis Rheum 21: 972–974, 1978.CrossRefPubMedGoogle Scholar
  384. 360.
    Coe MD, Hamer DH, Levy CS, et al.: Gonococcal pericarditis with tamponade in a patient with systemic lupus erythematosus. Arthritis Rheum 33: 1438–1441, 1990.CrossRefPubMedGoogle Scholar
  385. 361.
    Kaufman LD, Seifert FC, Eilbott DJ, et al.: Candida pericarditis and tamponade in a patient with systemic lupus erythematosus. Arch Intern Med 148: 715–717, 1988.CrossRefPubMedGoogle Scholar
  386. 362.
    Borenstein DG, Fye WB, Arnett FC, et al.: The myocarditis of systemic lupus erythematosus: association with myositis. Ann Intern Med 89: 619–624, 1978.CrossRefPubMedGoogle Scholar
  387. 363.
    Logar D, et al.: Anti-Ro antibodies associated with cardiac manifestations of SLE. Ann Rheum Dis 49: 627–629, 1990.CrossRefPubMedGoogle Scholar
  388. 364.
    Galve E, Candell-Riera J, Pigrau C, et al.: Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 319:817–823, 1988 (see also correspondence 320–322, 1989 ).Google Scholar
  389. 365.
    Jordan JM, Valenstein P, Kredich DW: Systemic lupus erythematosus with Libman-Sachs endocarditis in a 9-month-old infant with neonatal lupus erythematosus and congenital heart block. Pediatrics 84: 574–578, 1989.PubMedGoogle Scholar
  390. 366.
    Chartash EK, Lans DM, Paget SA, et al.: Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med 86: 407–412, 1989.CrossRefPubMedGoogle Scholar
  391. 367.
    Asherson RA, Gibson DG, Evans DW, et al.: Diagnostic and therapeutic problems in two patients with antiphospholipid antibodies, heart valve lesions, and transient ischaemic attacks. Ann Rheum Dis 47: 947–953, 1988.CrossRefPubMedGoogle Scholar
  392. 368.
    Leung W-H, Wong K-L, Lau C-P, et al.: Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 89: 411–419, 1990.CrossRefPubMedGoogle Scholar
  393. 369.
    Ford PM, Ford SE, Lillicrap DP: Association of lupus anticoagulant with severe valvular heart disease in systemic lupus erythematosus. J Rheumatol 15: 597–600, 1988.PubMedGoogle Scholar
  394. 370.
    Lubbe WF, Asherson RA: Intracardiac thrombus in systemic lupus erythematosus associated with lupus anticoagulant. Arthritis Rheum 31: 1453–1454, 1988.CrossRefPubMedGoogle Scholar
  395. 371.
    Maier WP, Ramirez HE, Miller SB: Complete heart block as the initial manifestation of systemic lupus erythematosus. Arch Intern Med 147: 170–171, 1987.CrossRefPubMedGoogle Scholar
  396. 372.
    Ishikawa S, Segar WE, Gilbert EF: Myocardial infarction in a child with systemic lupus erythematosus. Am J Dis Child 132: 696–698, 1978.PubMedGoogle Scholar
  397. 373.
    Bonfiglio TA, Botti RE, Hagstrom JWC: Coronary arteritis, occlusion and myocardial infarction due to systemic lupus erythematosus. Am Heart J 83: 153–158, 1972.CrossRefPubMedGoogle Scholar
  398. 374.
    Englund JA, Lucas RV Jr: Cardiac complications in children with systemic lupus erythematosus. Pediatrics 72: 724–730, 1983.PubMedGoogle Scholar
  399. 375.
    Friedman DM, Lazarus HM, Fierman AH: Acute myocardial infarction in pediatric systemic lupus erythematosus. J Pediatr 117: 263–266, 1990.CrossRefPubMedGoogle Scholar
  400. 376.
    Hosenpud JD, Montanaro A, Hart MV, et al.: Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 77: 286–292, 1984.CrossRefPubMedGoogle Scholar
  401. 377.
    Etheridge EM, Hoch-Legeti C: Lipid deposition in aortas in younger age groups following cortisone and adrenocorticotropic hormone. Am J Pathol 28: 315–332, 1952.PubMedGoogle Scholar
  402. 378.
    Alverson DC, Chase HP: Systemic lupus erythematosus in childhood presenting as hyperlipoproteinemia. J Pediatr 91: 72–75, 1977.CrossRefPubMedGoogle Scholar
  403. 379.
    Falko JM, Williams JC, Harvey DG, et al.: Hyperlipoproteinemia and multifocal neurologic dysfunction in systemic lupus erythematosus. 95: 523–529, 1979.Google Scholar
  404. 380.
    Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR: Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 83: 503–508, 1987.CrossRefPubMedGoogle Scholar
  405. 381.
    Ilowite NT, Samuel P, Ginzler E, Jacobson MS: Dyslipoproteinemia in pediatric systemic lupus. Arthritis Rheum 31: 859–863, 1988.CrossRefPubMedGoogle Scholar
  406. 382.
    Haupt HM, Moore CW, Hutchins CM: The lung in systemic lupus erythemato-sus: analysis of the pathologic changes in 120 patients. Am J Med 71: 791–798, 1981CrossRefPubMedGoogle Scholar
  407. 383.
    Pines A, Kaplinsky N, Olchovsky D, et al.: Pleuro-pulmonary manifestations of systemic lupus erythematosus: clinical features of its subgroups. Prognostic and therapeutic implications. Chest 88: 129–135, 1985.CrossRefPubMedGoogle Scholar
  408. 384.
    Saltzman HA, Alavi A, Greenspan RH, (PIOPED investigators), et al.: Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 263: 2753–2759, 1990.CrossRefGoogle Scholar
  409. 385.
    Gaither NS, Wortham D, Brinker JL: Current recommedations for use of pulmonary angiography. IM 12: 19–34, August 1991.Google Scholar
  410. 386.
    De Jongste JC, Neijens HJ, Duiverman EJ, et al.: Respiratory tract disease in systemic lupus erythematosus. Arch Dis Child 61: 478–483, 1986.CrossRefPubMedGoogle Scholar
  411. 387.
    Nadorra RL, Landing BH: Pulmonary lesions in childhood onset systemic lupus erythematosus: analysis of 26 cases, and summary of literature. Ped Pathol 7: 118, 1987.Google Scholar
  412. 388.
    Delgado EA, Malleson PN, Pirie GE, Petty RE: The pulmonary manifestations of childhood onset systemic lupus erythematosus. Semin Arthritis Rheum 19: 285–293, 1990.CrossRefPubMedGoogle Scholar
  413. 389.
    Gilleece MH, Evans CC, Bucknall RC: Steroid resistant pleural effusion in systemic lupus erythematosus treated with tetracycline pleurodesis. Ann Rheum Dis 47: 1031–1032, 1988.CrossRefPubMedGoogle Scholar
  414. 390.
    Segel AM, Calabrese LH, Ahmad M, et al.: The pulmonary manifestations of systemic lupus erythematosus. Semin Arthritis Rheum 14: 202–224, 1985.CrossRefGoogle Scholar
  415. 391.
    Gross M, Esterly JR, Earle RH: Pulmonary alterations in systemic lupus erythematosus. Am Rev Resp Dis 105: 572–577, 1972.PubMedGoogle Scholar
  416. 392.
    Tomaselli G, Gamsu G, Stulbary MS: Constrictive pericarditis presenting as pleural effusion of unknown origin. Arch Intern Med 149: 201–203, 1989.CrossRefPubMedGoogle Scholar
  417. 393.
    Jay MS, Jerath R, Van Derzalm T, et al.: Pneumothorax in an adolescent with fulminant systemic lupus erythematosus. J Adolescent Health Care 5: 142–144, 1984.CrossRefGoogle Scholar
  418. 394.
    Matthay RA, Schwartz MI, Petty TL, et al.: Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine 54: 397–409, 1974.CrossRefGoogle Scholar
  419. 395.
    Hedgpeth MT, Boulware DW: Interstitial pneumonitis in antinuclear antibody-negative systemic lupus erythematosus: a new clinical manifestation and possible association with Anti-Ro (SS-A) antibodies. Arthritis Rheum 31: 545548, 1988.Google Scholar
  420. 396.
    Rubin LA, Urowitz MB: Shrinking lung syndrome in SLE-a clinical pathologic study. J Rheumatol 10: 973–976, 1983.PubMedGoogle Scholar
  421. 397.
    Inoue T, Kanayame Y, Ohe A, et al.: Immunopathologic studies of pneumonitis in systemic lupus erythematosus. Ann Intern Med 91: 30–34, 1979.CrossRefPubMedGoogle Scholar
  422. 398.
    Fayemi AO: Pulmonary vascular disease in systemic lupus erythematosus. Am J Clin Pathol 65: 284–290, 1976.PubMedGoogle Scholar
  423. 399.
    Bjornsson J, Edwards WD: Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 60: 16–25, 1985.CrossRefPubMedGoogle Scholar
  424. 400.
    White RH, McGahan JP, Daschbach MM, Hartling RP: Diagnosis of deep-vein thrombosis using duplex ultrasound. Ann Intern Med 111: 297–304, 1989.CrossRefPubMedGoogle Scholar
  425. 401.
    Hull RD, Raskob GE, Coates G, et al.: A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med 149: 2549–2555, 1989.CrossRefPubMedGoogle Scholar
  426. 402.
    Marder VJ, Sherry S: Thrombolytic therapy: current status, part II. N Engl J Med 318: 1585–1593, 1988.CrossRefPubMedGoogle Scholar
  427. 403.
    Mitchell JP, Trulock EP: Tissue-Plasminogen activator for pulmonary embolism resulting in shock: Two case reports and discussion of the literature. Am J Med 90: 255–260, 1991.PubMedGoogle Scholar
  428. 404.
    Rajani KB, Ashbacher LV, Kinney TR: Pulmonary hemorrhage and systemic lupus erythematosus. J Pediatr 93: 810–812, 1978.CrossRefPubMedGoogle Scholar
  429. 405.
    Abud-Mendoza C, Diaz-Jouanen E, Alarcon-Segovia D: Fatal pulmonary hemorrhage in systemic lupus erythematosus. Occurrence without hemoptysis. J Rheumatol 12: 558–561, 1985.PubMedGoogle Scholar
  430. 406.
    Miller RW, Salcedo JR, Fink RJ, et al.: Pulmonary hemorrhage in pediatric patients with systemic lupus erythematosus. J Pediatr 108: 576–579, 1986.CrossRefPubMedGoogle Scholar
  431. 407.
    Clinicopathologic Conference: anemia, abdominal pain, and death in a 19-yearold woman. Am J Med 83:93–100, 1987.Google Scholar
  432. 408.
    Castaneda S, Herrero-Beaumont G, Valenzuela A, et al.: Massive pulmonary hemorrhage: fatal complication of systemic lupus erythematosus. J Rheumatol 12: 186–187, 1985.PubMedGoogle Scholar
  433. 409.
    Ramirez RE, Glasier C, Kirks D, et al.: Pulmonary hemorrhage associated with systemic lupus erythematosus in children. Radiology 152: 409–412, 1984.PubMedGoogle Scholar
  434. 410.
    Howe HS, Boey ML, Fong KY, Feng PH: Pulmonary haemorrhage, pulmonary infarcation, and the lupus anticoagulant. Ann Rheum Dis 47: 869–872, 1988.CrossRefPubMedGoogle Scholar
  435. 411.
    Leatherman JW, Davies SF, Hoidal JR: Alveolar hemorrhage syndromes: diffuse microvascular lung hemorrhage in immune and idiopathic disorders. Medicine 63: 343–361, 1984.CrossRefPubMedGoogle Scholar
  436. 412.
    Schwab EP, Freundlich B, Callegan PE: Prognosis and therapy of pulmonary alveolar hemorrhage in systemic lupus erythematosus. Arthritis Rheum 34: S188, 1991.Google Scholar
  437. 413.
    Simpson IJ, Doak PB, Williams LC, et al.: Plasma exchange in Goodpasture’s syndrome. Am J Nephrol 2: 301–311, 1982.CrossRefPubMedGoogle Scholar
  438. 414.
    Raz E, Bursztyn M, Rosenthal T, Rubinow A: Severe recurrent lupus laryngitis. Am J Med 92: 109–110, 1992.CrossRefPubMedGoogle Scholar
  439. 415.
    Hellman DB, Petri M, Whiting-O’Keefe Q: Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine 66: 341–348, 1987.CrossRefGoogle Scholar
  440. 416.
    Nived O, Sturfelt G, Wollheim F: Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group. Q J Med 218: 271–287, 1985.Google Scholar
  441. 417.
    Boghossian SH, Isenberg DA, Wright G, et al.: Effect of high-dose methylprednisolone therapy on phagocyte function in systemic lupus erythematosus. Ann Rheum Dis 43: 541–550, 1984.CrossRefPubMedGoogle Scholar
  442. 418.
    Orth RW, Weisman MH, Cohen AH, et al.: Lupus cystitis: primary bladder manifestations of systemic lupus erythematosus. Ann Intern Med 98: 323–326, 1983.CrossRefPubMedGoogle Scholar
  443. 419.
    Abramson S, Kramer S, Radin A, et al.: Salmonella bacteremia in systemic lupus erythematosus: eight-year experience at a municipal hospital. Arthritis Rheum 28: 75–79, 1985.CrossRefPubMedGoogle Scholar
  444. 420.
    Frayha RA, Jizi I, Saadeh G: Salmonella typhimurium bacteriuria. An increased infection rate in systemic lupus erythematosus. Arch Intern Med 145: 645–647, 1985.CrossRefPubMedGoogle Scholar
  445. 421.
    Malleson P, Petty RE, Nadel H, Dimmick JE: Functional asplenia in childhood onset systemic lupus erythematosus. J Rheumatol 15: 1648–1652, 1988.PubMedGoogle Scholar
  446. 421a.
    Lipnick RN, Karsh J, Stahl NI, et al.: Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J Rheumatol 12: 1118–1121, 1985.Google Scholar
  447. 422.
    Johnson WM, Gall EP: Fatal coccidiodomycosis in collagen vascular diseases. J Rheumatol 10: 79–84, 1983.PubMedGoogle Scholar
  448. 423.
    Livneh A, Coman EA, Cho S, Lipstein-Kresch E: Strongyloides stercoralis hyperinfection mimicking systemic lupus erythematosus flare. Arthritis Rheum 31: 930–931, 1988.CrossRefPubMedGoogle Scholar
  449. 424.
    Ashman RF, White RH, Wiesenhutter C, et al.: Panhypogammaglobulinemia in systemic lupus erythematosus: in vitro demonstration of multiple cellular defects. J Allergy Clin Immunol 70: 465, 1982.CrossRefPubMedGoogle Scholar
  450. 425.
    Sussman GL, Rivera VJ, Kohler PF: Transition from systemic lupus erythematosus to common variable hypogammaglobulinemia. Ann Intern Med 99: 3235, 1983.CrossRefGoogle Scholar
  451. 426.
    Goldstein R, Izaguirre C, Smith CD, et al.: Systemic lupus erythematosus and common variable panhypogammaglobulinemia: a patient with absence of circulating B cells. Arthritis Rheum 28: 100–103, 1985.CrossRefPubMedGoogle Scholar
  452. 427.
    Stein A, Winkelstein A, Agarwal A: Concurrent systemic lupus erythematosus and common variable hypogammaglobulinemia. Arthritis Rheum 28: 462–465, 1985.CrossRefPubMedGoogle Scholar
  453. 428.
    Baum CG, Chiorazzi N, Frankel S, Shepherd GM: Conversion of systemic lupus erythematosus to common variable hypogammaglobulinemia. Am J Med 87: 449–456, 1989.CrossRefPubMedGoogle Scholar
  454. 429.
    Tsokos GC, Smith PL, Balow JE: Development of hypogammaglobulinemia in a patient with systemic lupus erythematosus. Am J Med 81: 1081–1084, 1986.CrossRefPubMedGoogle Scholar
  455. 430.
    Jacobs JC: Transient hypogammaglobulinemia (TH) with sepsis. A manifestation of childhood systemic lupus erythematosus (SLE) which improves with more immunosuppressive therapy. Pediatr Res 29 (No. 4, Pt. 2): 158A, 1991.Google Scholar
  456. 431.
    Akashi K, Nagasawa K, Mayumi T, et al.: Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J Rheumatol 17: 375–379, 1990.PubMedGoogle Scholar
  457. 432.
    Bernstein B, Koster-King K, Singsen B, et al.: Sjögren’s syndrome in childhood Arthritis Rheum 20: 361–362, 1977.Google Scholar
  458. 433.
    Athreya B, Norman ME, Myers AR, et al.: Sjögren’s syndrome in children. Pediatrics 59: 931–938, 1977.PubMedGoogle Scholar
  459. 434.
    Jackson J, Anderson L, Schur P, et al.: Sjögren’s syndrome in juvenile rheumatoid arthritis (JRA), abstracted. Arthritis Rheum 16: 122, 1973.Google Scholar
  460. 435.
    Talal N, Moutsopoulos HM, Kassan S, (eds): Sjogren’s Syndrome: Clinical and Immunological Aspects. Springer-Verlag: Heidelberg, 1987.Google Scholar
  461. 436.
    Kassan SS, Thomas TL, Moutsopoulos HM, et al.: Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89: 888–892, 1978.CrossRefPubMedGoogle Scholar
  462. 437.
    Fraga A, Gudino J, Ramos-Niembro F, et al.: Mixed connective tissue disease in childhood: relationship with Sjögren’s syndrome. Am J Dis Child 132: 263–266, 1978.PubMedGoogle Scholar
  463. 438.
    Singsen BH, Swanson VL, Bernstein BH, et al.: A histologic evaluation of mixed connective tissue disease in childhood. Am J Med 68: 710–717, 1980.CrossRefPubMedGoogle Scholar
  464. 439.
    De Clerck LS, Coutteneye MM, de Broe ME, Stevens WJ: Acquired immunodeficiency syndrome mimicking Sjogren’s Syndrome and systemic lupus erythematosus. Arthritis Rheum 31: 272–275, 1988.CrossRefPubMedGoogle Scholar
  465. 440.
    Flescher E, Talal N: Do viruses contribute to the development of Sjogren’s Syndrome? Am J Med 90: 283–294, 1991.PubMedGoogle Scholar
  466. 441.
    Harley JB: Autoantibodies in Sjogren’s Syndrome. In Sjogren’s Syndrome: Clinical and Immunological Aspects. Springer-Verlag, Berlin, New York, 1987, pp. 218–234.Google Scholar
  467. 442.
    Provost TT, Alexander EL, Reichlin M: The relationship between anti-Ro (SSA) precipitin antibody positive Sjogren’s syndrome and anti-Ro (SS-A) precipitin antibody positive lupus erythematosus. Ibid, pp. 247–257.Google Scholar
  468. 443.
    Eberhard BA, Laxer RM, Eddy AA, Silverman ED: Presence of thyroid abnormalities in children with systemic lupus erythematosus. J Pediatr 119: 277–279, 1990.Google Scholar
  469. 444.
    Miller FW, Moore GF, Weintraub BD, Steinberg AD: Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus. Arthritis Rheum 30:1124–1131, 1987 (see also correspondence 31: 1079–1080, 1980 ).Google Scholar
  470. 445.
    Franzen P, Friman C, Pettersson T, et al.: Combined pure red cell aplasia and primary autoimmune hypothyroidism in systemic lupus erythematosus. Arthitis Rheum 30: 839–840, 1987.CrossRefGoogle Scholar
  471. 446.
    Utiger RD: The pathogenesis of autoimmune thyroid disease. N Engl J Med 325: 278–279, 1991.CrossRefPubMedGoogle Scholar
  472. 447.
    Tucker WS, Niblack GD, McLean RH, et al.: Serositis with autoimmune endocrinopathy: clinical and immunogenetic features. Medicine 66: 138–146. 1987.CrossRefPubMedGoogle Scholar
  473. 448.
    Case records of the Massachusetts General Hospital. Case 15–1985. N Engl J Med 312: 976–983, 1985.CrossRefGoogle Scholar
  474. a.Levy EN, Ramsey-Goldman R, Kahl LE: Adrenal insufficiency in two women with anticardiolipin antibodies. Cause and effect? Arthritis Rheum 33: 1842–1846, 1990.CrossRefGoogle Scholar
  475. 449.
    Klipper AR, Stevens MB, Zizic TM, et al.: Ischemic necrosis of bone in systemic lupus erythematosus. Medicine 55: 251–257, 1976.CrossRefPubMedGoogle Scholar
  476. 450.
    Felson DT, Anderson JJ: A cross-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet 1: 902–905, 1987.CrossRefPubMedGoogle Scholar
  477. 451.
    Bergstein JM, Wiens C, Fish AJ, et al.: Avascular necrosis of bone in systemic lupus erythematosus. J Pediatr 85: 31–35, 1974.CrossRefPubMedGoogle Scholar
  478. 452.
    Abeles M, Urman JD, Rothfield NF: Aseptic necrosis of bone in systemic lupus erythematosus: relationship to corticosteroid therapy. Arch Intern Med 138: 750–754, 1978.CrossRefPubMedGoogle Scholar
  479. 453.
    Crossman J, Koval NS, Condemi JJ: Systemic lupus erythematosus: Bilateral aseptic necrosis of hip. NY State J Med 75: 1523–1526, 1975.Google Scholar
  480. 454.
    Zizic TM, Hungerford DS, Stevens MB: Ischemic bone necrosis in systemic lupus erythematosus. Medicine 59: 134–148, 1980.CrossRefPubMedGoogle Scholar
  481. 455.
    Hanly JG, Gladman DD, Rose TH, et al.: Lupus pregnancy. A prospective study of placental changes. Arthritis Rheum 31: 358–366, 1988.CrossRefPubMedGoogle Scholar
  482. 456.
    Wong K, Chan F, Lee C: SLE does not preclude normal pregnancy. Arch Intern Med 151: 269–273, 1991.CrossRefPubMedGoogle Scholar
  483. 457.
    Estes D, Larson DL: Systemic lupus erythematosus and pregnancy. Clin Obstet Gynecol 8: 307–321, 1965.CrossRefGoogle Scholar
  484. 458.
    McGee CD, Makowski EL: Systemic lupus erythematosus in pregnancy. Am J Obstet Gynecol 107: 1008–1012, 1970.PubMedGoogle Scholar
  485. 459.
    Bear R: Pregnancy and lupus nephritis. Obstet Gynecol 47: 715–718, 1975.Google Scholar
  486. 460.
    McCune AB, Weston WL, Lee LA: Maternal and fetal outcome in neonatal lupus erythematosus. Ann Intern Med 106: 518–523, 1987.CrossRefPubMedGoogle Scholar
  487. 461.
    Gatenby PA: Systemic lupus erythematosus and pregnancy. Aust NZ J Med 19: 261–278, 1989.CrossRefGoogle Scholar
  488. 461a.
    Shibata S, Sasaki T, Hirabayashi Y, et al.: Risk factors in the pregnancy of patients with systemic lupus erythematosus: association of hypocomplementemia with poor prognosis. Ann Rheum Dis 51: 619–623, 1992.Google Scholar
  489. 462.
    Stafford-Brady FJ, Gladman DD, Urowitz MB: Successful pregnancy in systemic lupus erythematosus with an untreated lupus anticoagulant. Arch Intern Med 148: 1647–1648, 1988.CrossRefPubMedGoogle Scholar
  490. 463.
    Siamopoulou-Mavridou A, Manoussakis MN, Mavridis AK, Moutsopoulos HM: Outcome of pregnancy in patients with autoimmune rheumatic disease before the disease onset. Ann Rheum Dis 47: 982–987, 1988.CrossRefPubMedGoogle Scholar
  491. 464.
    Lubbe WF, Palmer SJ, Butler WS, Liggins GC: Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet 1: 1361–1363, 1983.CrossRefPubMedGoogle Scholar
  492. 465.
    Harris EN, Hughes GRV, Gharavi AE: Thrombosis, fetal loss and antiphospholipid antibodies. Clin Aspects Autoimmun 1: 1–11, 1986.Google Scholar
  493. 466.
    Ramsey-Goldman R, Mientus JM, Medsger TA Jr.: Pregnancy outcome in women with systemic lupus erythematosus (SLE) treated with immunosuppressive drugs. Arthritis Rheum 33: S28, 1990.Google Scholar
  494. 467.
    Buyon JP, Swersky SH, Fox HE, et al.: Intrauterine therapy for presumptive fetal myocarditis with acquired heart block due to systemic lupus erythematosus. Experience with a mother with a predominance of SS-B (La) antibodies. Arthritis Rheum 30: 44–49, 1987.CrossRefPubMedGoogle Scholar
  495. 468.
    Bierman FZ, Baxi L, Jaffe I, Driscoll J: Fetal hydrops and congenital complete heart block: response to maternal steroid therapy. J Pediatr 112: 646–648, 1988.CrossRefPubMedGoogle Scholar
  496. 469.
    Lockshin MD: Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum 32:665–670, 1989 (see also correspondence 33: 605606, 1990 ).Google Scholar
  497. a.Buyon JP: Systemic Lupus Erythematosus and Pregnancy. Cliniguide to Rheumatology 1 (#4): 1–8, 1991.Google Scholar
  498. 470.
    Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M: Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status. Am J Med 91: 345–353, 1991.CrossRefPubMedGoogle Scholar
  499. 471.
    Buyon JP, Cronstein BN, Morris M, et al.: Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia. Am J Med 81: 194–200, 1986.CrossRefPubMedGoogle Scholar
  500. a.Soscia PN, Zurier RB. Drug therapy of rheumatic diseases during pregnancy. Bull Rheum Dis 41:#2: 1–3, 1992.Google Scholar
  501. 472.
    Vonderheid EC, Koblenzer PJ, Ming PML, et al.: Neonatal lupus erythematosus. Arch Dermatol 112: 698–705, 1976.CrossRefPubMedGoogle Scholar
  502. 473.
    Crittenen IH: Rheumatoid arthritis in the mother of five siblings with congenital heart block. N Engl J Med 299: 491–492, 1978.PubMedGoogle Scholar
  503. 474.
    Lockshin MD, Bonfa E, Elkon K, Druzin ML: Neonatal lupus risk to newborns of mothers with systemic lupus erythematosus. Arthritis Rheum 31: 697–701, 1988.CrossRefPubMedGoogle Scholar
  504. 475.
    Watson RM, Lane AT, Barnett NK, et al.: Neonatal lupus erythematosus. A clinical, serological and immunogenetic study with review of the literature. Medicine 63: 362–378, 1984.CrossRefPubMedGoogle Scholar
  505. 476.
    Buyon JP, Winchester R: Congenital complete heart block. A human model of passively acquired autoimmune injury. Arthritis Rheum 33: 609–614, 1990.CrossRefPubMedGoogle Scholar
  506. 477.
    Gaither KK, Fox OF, Yamagata H, et al.: Implications of anti-Ro/Sjogren’s syndrome A antigen autoantibody in normal sera for autoimmunity. J Clin Invest 79: 841–846, 1987.CrossRefPubMedGoogle Scholar
  507. 478.
    Buyon JP, Ben-Chetrit E, Karp S, et al.: Acquired congenital heart block. Pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus. J Clin Invest 84: 627–634, 1989.CrossRefPubMedGoogle Scholar
  508. 479.
    Arnaiz-Villena A, Vaquez-Rodriguez JJ, Vicario JL, et al.: Congenital heart block immunogenetics. Evidence of an additional role of HLA Class III antigens and independence of Ro autoantibodies. Arthritis Rheum 32: 1421–1426, 1989.CrossRefPubMedGoogle Scholar
  509. 480.
    Provost TT, Watson R, Gammon WR, et al.: The neonatal lupus syndrome associated with U 1 RNP (nRNP) antibodies. N Engl J Med 316: 1135–1138, 1987.CrossRefPubMedGoogle Scholar
  510. a.Alexander E, Buyon JP, Provost TT, Guarnieri T: Anti-Ro/SS-A antibodies in the pathophysiology of congenital heart block in neonatal lupus syndrome, an experimental model. In vitro electrophysiologic and immunocytochemical studies. Arthritis Rheum 35:176–189, 1992.Google Scholar
  511. 481.
    Callen JP, Fowler JF, Kulick KB, et al.: Neonatal lupus erythematosus occuring in one fraternal twin. Serologic and immunogenetic studies. Arthritis Rheum 28: 271–305, 1985.CrossRefPubMedGoogle Scholar
  512. 482.
    Chameides L, Truex RC, Vetter V, et al.: Association of maternal systemic lupus erythematosus with congenital complete heart block. N Engl J Med 297: 1204–1208, 1977.CrossRefPubMedGoogle Scholar
  513. 483.
    Nolan RJ, Shulman ST, Victorica BE: Congenital complete heart block associated with maternal mixed connective tissue disease. J Pediatr 95: 420–422, 1979.CrossRefPubMedGoogle Scholar
  514. 484.
    Hardy JD, Banwell GS, Beach R, et al.: Congenital complete heart block in the newborn associated with maternal systemic lupus erythematosus and other connective tissue disorders. Arch Dis Child 54: 7–13, 1979.CrossRefPubMedGoogle Scholar
  515. 485.
    Editorial: Systemic lupus in the newborn. Lancet 1: 859, 1979.Google Scholar
  516. 486.
    Doshi N, Smith B, Klionsky B: Congenital pericarditis due to maternal lupus erythematosus. J Pediatr 96: 699–701, 1980.CrossRefPubMedGoogle Scholar
  517. 487.
    Klippel JH, Grimley PM, Decker JL: Lymphocyte inclusions in newborns of mothers with systemic lupus erythematosus. N Engl J Med 290: 97–98, 1974.CrossRefGoogle Scholar
  518. 488.
    Levy SB, Goldsmith LA, Morohashi M, et al.: Tubuloreticular inclusions in neonatal lupus erythematosus. JAMA 235: 2743–2744, 1976.CrossRefPubMedGoogle Scholar
  519. 489.
    Jones MM, Lidsky MD, Brewer EJ, et al.: Congenital cytomegalovirus infection and maternal systemic lupus erythematosus: a case report. Arthritis Rheum 29: 1402–1404, 1986.CrossRefPubMedGoogle Scholar
  520. 490.
    Rider LG, Sherry DD, Glass ST: Neonatal lupus erythematosus simulating transient myasthenia gravis at presentation. J Pediatr 118: 417–419, 1991.CrossRefPubMedGoogle Scholar
  521. 491.
    Laxer RM, Roberts EA, Gross KR, et al.: Liver disease in neonatal lupus erythematosus. J Pediatr 116: 238–242, 1990.CrossRefPubMedGoogle Scholar
  522. 492.
    Ty A, Fine BP: Infantile systemic lupus erythematosus (SLE) associated with chromosomal abnormalities presenting as nephrotic syndrome, abstracted. Pediatr Res 12: 548, 1978.CrossRefGoogle Scholar
  523. 493.
    Taylor PV, Scott JS, Gerlis LM, et al.: Maternal antibodies against fetal cardiac antigens in congenital complete heart block. N Engl J Med 315: 667–672, 1986.CrossRefPubMedGoogle Scholar
  524. 494.
    Lanham JG, Walport MJ, Hughes GRV: Congenital heart block and familial connective tissue disease. J Rheumatol 10: 823–825, 1983.PubMedGoogle Scholar
  525. 495.
    Reichlin M, Friday K, Harley JB: Complete congenital heart block followed by anti-Ro/SSA in adult life. Studies of an informative family. Am J Med 84: 339344, 1988.Google Scholar
  526. 496.
    Ty A, Fine B: Membranous nephritis in infantile systemic lupus erythematosus associated with chromosomal abnormalities. Clin Nephrol 12: 137–141, 1979.PubMedGoogle Scholar
  527. 497.
    Cummings NP, Hansen J, Hollister JR: Systemic lupus erythematosus in a premature infant. Arthritis Rheum 28: 573–575, 1985.CrossRefPubMedGoogle Scholar
  528. 498.
    Anderson JR: Intracerebral calcification in a case of systemic lupus erythematosus with neurological manifestations. Neuropathol Appl Neurobiol 7: 161–166, 1981.CrossRefPubMedGoogle Scholar
  529. 499.
    Beernick DH, Miller JJ: Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children. J Petiatr 82: 113–117, 1973.CrossRefGoogle Scholar
  530. 500.
    Singsen BH, Fishman L, Hanson V: Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants. Pediatrics 57: 529–534, 1976.PubMedGoogle Scholar
  531. 501.
    Rubin RL: Drug-induced lupus. Clin Aspects Autoimmun 2: 16–29, 1988.Google Scholar
  532. 502.
    Hess EV, Mongey A-B: Drug-related Lupus. Bull Rheum Dis 40:#4, 1–8, 1991. Arthritis Foundation.Google Scholar
  533. 503.
    Litwin A, Adams LE, Zimmer H, et al.: Prospective study of immunologic effects of hydralazine in hypertensive patients. Clin Pharmacol Ther 29: 447456, 1981.Google Scholar
  534. 504.
    Steen VD, Ramsey-Goldman R: Phenothiazine-induced systemic lupus erythematosus with superior vena cava syndrome: case report and review of the literature. Arthritis Rheum 31: 923–926, 1988.CrossRefPubMedGoogle Scholar
  535. 505.
    Totoritis MC, Tan EM, McNally EM, Rubin RL: Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus. N EnglJ Med 318:1431–1436, 1988 (see also Editorial pp. 1460–1462).Google Scholar
  536. 506.
    Enzenauer RJ, West SG, Rubin RL: D-Penicillamine-induced lupus erythematosus. Arthritis Rheum 33: 1582–1585, 1990.CrossRefPubMedGoogle Scholar
  537. 507.
    Irias JJ: Hydralazine-induced lupus erythematosus-like syndrome. Am J Dis Child 129: 862–864, 1975.PubMedGoogle Scholar
  538. 507a.
    Tolaymat A, Leventhal B, Sakarcan A, et al.: Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr 120: 429–432, 1992.Google Scholar
  539. 508.
    Nordstrom DM, West SG, Rubin RL: Methyldopa-induced systemic lupus erythematosus. Arthritis Rheum 32: 205–208, 1989.CrossRefPubMedGoogle Scholar
  540. 509.
    Woosley RL, Drayer DE, Reidenberg MM, et al.: Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 298: 1157–1159, 1978.CrossRefPubMedGoogle Scholar
  541. 510.
    Batchelor JR, Weish KI, Tinoco RM, et al.: Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1: 1107–1109, 1980.CrossRefPubMedGoogle Scholar
  542. 511.
    Speirs C, Fielder AHL, Chapel H, et al.: Complement system protein C4 and susceptibility to hydralazine-induced systemic lupus erythematosus. Lancet 1: 922–924, 1989.CrossRefPubMedGoogle Scholar
  543. 512.
    Massimo L, Pasino M, Rosando-Vadala C, et al.: Immunological side-effects of anticonvulsants. Lancet 1: 860, 1976.CrossRefPubMedGoogle Scholar
  544. 513.
    Kirtland HH, Mohler DN, Horwitz DA: Methyldopa inhibition of suppressor-lymphocyte function. N Engl J Med 302: 825–832, 1980.CrossRefPubMedGoogle Scholar
  545. 514.
    Dosch H-M, Jason J, Gelfand EW: Transient antibody deficiency and abnormal T suppressor cells induced by phenytoin. N Engl J Med 306: 406–409, 1982.CrossRefPubMedGoogle Scholar
  546. 515.
    Craft JE, Radding JA, Harding MW, et al.: Autoantigenic histone epitopes: a comparison between procainamide-and hydralazine-induced lupus. Arthritis Rheum 30: 689–694, 1987.CrossRefPubMedGoogle Scholar
  547. 516.
    Epstein A, Barland P: The diagnostic value of antihistone antibodies in drug-induced lupus erythematosus. Arthritis Rheum 28:158–162, 1985 (see also correspondence p. 148, 1986 ).Google Scholar
  548. 517.
    Shear NH, Spielberg SP: Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 82: 1826–1832, 1988.CrossRefPubMedGoogle Scholar
  549. 518.
    Miller JJ III: Drug-induced lupus-like syndromes in children. Arthritis Rheum 20: 308–311, 1977.PubMedGoogle Scholar
  550. 519.
    Weinstein J: Hypocomplementemia in hydralazine-associated systemic lupus erythematosus. Am J Med 65: 553–556, 1978.CrossRefPubMedGoogle Scholar
  551. 520.
    Sharp GC, Irvin WS, Tan EM, et al.: Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to extractable nuclear antigen (ENA). Am J Med 52: 148–159, 1972.CrossRefPubMedGoogle Scholar
  552. 521.
    Sharp GC: Mixed connective tissue disease. Bull Rheum Dis 25: 828–830, 1975.Google Scholar
  553. 522.
    Sharp GC, Irvin WS, May CM, et al.: Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systemic lupus erythematosus and other rheumatic disease. N Engl J Med 296: 1149–1154, 1976.CrossRefGoogle Scholar
  554. 523.
    Hamburger M, Hodes S, Barland P: The incidence and clinical significance of antibodies to extractable nuclear antigens. Am J Med Sci 273: 21–28, 1977.CrossRefPubMedGoogle Scholar
  555. 524.
    Singsen BH, Bernstein BH, Kornreich HK, et al.: Mixed connective tissue disease in childhood: a clinical and serologic survey. J Pediatr 90: 893–900, 1977.CrossRefPubMedGoogle Scholar
  556. 525.
    Baldassare A, Weiss T, Auclair R, et al.: Mixed connective tissue disease (MCTD) in children, abstracted. Arthritis Rheum 19: 788, 1976.Google Scholar
  557. 526.
    Hutto JH, Ayoub EM: Mixed connective tissue disease in children, abstracted. Pediatr Res 11: 488, 1977.CrossRefGoogle Scholar
  558. a.Oetgen WJ, Boice JA, Lawless OJ: Mixed connective tissue disease in children and adolescents. Pediatrics 67: 333–337, 1981.Google Scholar
  559. 527.
    Alpert MA, Goldberg SH, Singsen BH, et al.: Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 68: 1182–1193, 1983.CrossRefPubMedGoogle Scholar
  560. 528.
    Savouret J-F, Chudwin DS, Wara DW, et al.: Clinical and laboratory findings in childhood mixed connective tissue disease: presence of antibody to ribonucleoprotein containing the small nuclear ribonucleic acid U1. J Pediatr 102: 841, 1983.CrossRefPubMedGoogle Scholar
  561. 529.
    Nimelstein SH, Brody S, McShane D, et al.: Mixed connective tissue disease: a subsequent evaluation of the orginal 25 patients. Medicine 59: 239–248, 1980.CrossRefPubMedGoogle Scholar
  562. 530.
    Prakash UBS, Luthra HS, Divertie MB: Intrathoracic manifestations in mixed connective tissue disease. Mayo Clin Proc 60: 813–821, 1985.CrossRefPubMedGoogle Scholar
  563. 531.
    Lemmer JP, Curry NH, Mallory JH, Waller MV: Clinical characteristics and course in patients with high titer anti-RNP antibodies. J Rheumatol 9: 536–542, 1982.PubMedGoogle Scholar
  564. 532.
    Fisher DE, Reeves WH, Wisniewolski R, et al.: Temporal shifts from Sm to ribonucleoprotein reactivity in systemic lupus erythematosus. Arthritis Rheum 28: 1348–1355, 1985.CrossRefPubMedGoogle Scholar
  565. 533.
    ter Borg EJ, Horst G, Hummel E, et al.: Sequential development of antibodies to specific Sm polypeptides in a patient with systemic lupus erythematosus: evidence for independent regulation of anti-double-stranded DNA and Anti-Sm antibody production. Arthritis Rheum 31: 1563–1567, 1988.CrossRefPubMedGoogle Scholar
  566. 534.
    Asherson RA, Angus H, Matthews JA, et al.: The progressive systemic sclerosis/ systemic lupus overlap: an unusual clinical progression. Ann Rheum Dis 50: 323–327, 1991.CrossRefPubMedGoogle Scholar
  567. 535.
    Biesecker G, Lavin L, Zisking H, Koeffler D: Cutaneous localization of the membrane attack complex in discoid and systemic lupus erythematosus. N Engl J Med 306: 264–270, 1982.CrossRefPubMedGoogle Scholar
  568. 536.
    Sontheimer RD, Maddison PJ, Reichlin M, et al.: Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 97: 664–671, 1982.CrossRefPubMedGoogle Scholar
  569. 537.
    Callen JP, Klein J: Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum 31: 1007–1013, 1988.CrossRefPubMedGoogle Scholar
  570. 538.
    Weinstein C, Miller MH, Axtens R, et al.: Lupus and lupus-cutaneous manifestations in systemic lupus erythematosus. Aust NZ J Med 17: 501–506, 1987.CrossRefGoogle Scholar
  571. 539.
    Weinstein CL, Littlejohn GO, Thomson NM, et al.: Severe visceral disease in subacute cutaneous lupus erythematosus. Arch Dermatol 123: 638–640, 1987.CrossRefPubMedGoogle Scholar
  572. 540.
    Newton RC, Jorizzo JL, Solomon AR Jr, et al.: Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 122: 170–176, 1986.CrossRefPubMedGoogle Scholar
  573. 541.
    Nichalas J-F, Thivolet J: Interferon alfa therapy in severe unresponsive subacute cutaneous lupus erythematosus. N Engl J Med 321: 1550–1551, 1989.CrossRefGoogle Scholar
  574. 542.
    Ehrlich GE: Systemic lupus erythematosus. JAMA 232: 1361–1365, 1975.CrossRefPubMedGoogle Scholar
  575. 543.
    Jacobs JC: Treatment of systemic lupus erythematosus in childhood. Arthritis Rheum 20: 304–307, 1977.CrossRefPubMedGoogle Scholar
  576. 544.
    Wasner CK, Fries JF: Treatment decisions in systemic lupus erythematosus. Arthritis Rheum 23: 283–286, 1980.CrossRefPubMedGoogle Scholar
  577. 545.
    Gladman DD, Urowitz MD, Keystone EC: Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 111: 210–216, 1979.CrossRefGoogle Scholar
  578. 546.
    Wallace DJ, Podell TE, Weiner JM, et al.: Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med 72: 209–220, 1982.CrossRefPubMedGoogle Scholar
  579. 547.
    Donadio JV Jr: Cytotoxic-drug treatment of lupus nephritis. N Engl J Med 311: 528–529, 1984.CrossRefPubMedGoogle Scholar
  580. 548.
    Donadio JV Jr, Holley KE, Ferguson RH, et al.: Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N EnglJ Med 299: 1151–1155, 1978.CrossRefGoogle Scholar
  581. 549.
    Ibid: Letter to the Editor. N Engl J Med 300: 564–565, 1979.CrossRefGoogle Scholar
  582. 550.
    Schur PH, Sandson J: Immunological factors and clinical activity in systemic lupus erythematosus. N Engl J Med 278: 533–538, 1968.CrossRefPubMedGoogle Scholar
  583. 551.
    Bardana EJ, Harbeck RJ, Hoffman AA, et al.: The prognostic and therapeutic implications of DNA: anti-DNA immune complexes in systemic lupus erythematosus (SLE). Am J Med 59: 515–522, 1975.CrossRefPubMedGoogle Scholar
  584. 552.
    Hecht B, Siegel N, Adler M, et al.: Prognostic indices in lupus nephritis. Medicine 55: 163–181, 1976.CrossRefPubMedGoogle Scholar
  585. 553.
    Urman JD, Rothfield NF: Corticosteroid treatment in systemic lupus erythematosus: Survival studies. JAMA 238: 2270–2276, 1977.CrossRefGoogle Scholar
  586. 554.
    Swaak AJG, Aarden LA, Van Exps LWS, et al.: Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 22: 226–235, 1979.CrossRefPubMedGoogle Scholar
  587. 555.
    Helve T, Kurki P, Teppo A-M, Wegelius O: DNA antibodies and complement in SLE patients. A follow-up study. Rheumatol Int 3: 129–132, 1983.CrossRefPubMedGoogle Scholar
  588. 556.
    Laitman RS, Glicklich D, Sablay LB, et al.: Effect of long-term normalization of serum complement levels on the course of lupus nephritis. Am J Med 87: 13 2138, 1989.Google Scholar
  589. 557.
    ter Borg EJ, Horst G, Hummel EJ, et al.: Measurement of increases in antidouble-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 33: 634–643, 1990.CrossRefPubMedGoogle Scholar
  590. 558.
    Nossent JC, Huysen V, Smeenk RJT, Swaak AJG: Low avidity antibodies to double stranded DNA in systemic lupus erythematosus: a longitudinal study of their clinical significance. Ann Rheum Dis 48: 677–682, 1989.CrossRefPubMedGoogle Scholar
  591. 559.
    Swaak AJG, Groenwold J, Bronsveld W: Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45: 359–366, 1986.CrossRefPubMedGoogle Scholar
  592. 560.
    Jarrett MP, Walter L, Barland P, et al.: The effect of continuous normalization of serum complement (CHSO) on the course of lupus nephritis. A five year prospective study, abstracted. Arthritis Rheum 23: 697, 1980.Google Scholar
  593. 561.
    Garin EH, Donnelly WH, Shulman ST, et al.: The significance of serial measurements of serum complement C3 and C4 components and DNA binding capacity in patients with lupus nephritis. Clin Nephrol 12: 148–155, 1979.PubMedGoogle Scholar
  594. 562.
    Pollak VE, Pirani CL, Kark RM: Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis. J Lab Clin Med 57: 495–511, 1961.PubMedGoogle Scholar
  595. 563.
    Rothfield NF, McCluskey R, Baldwin DS: Renal disease in systemic lupus erythematosus. N Engl J Med 269: 537–544, 1963.CrossRefPubMedGoogle Scholar
  596. 564.
    Hagge WW, Burke EC, Stickler GB: Treatment of systemic lupus erythematosus complicated by nephritis in children. Rediatrics 40: 822–827, 1967.Google Scholar
  597. 565.
    Ackerman GL: Alternate-day steroid therapy in lupus nephritis. Ann Intern Med 72: 511–519, 1970.CrossRefPubMedGoogle Scholar
  598. 566.
    Donadio JV Jr, Holley KE, Wagoner RD, et al.: Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Ann Intern Med 77: 829–835, 1972.CrossRefPubMedGoogle Scholar
  599. 567.
    Balow JE, Austin HA III, Tsokos GC, et al.: Lupus nephritis. Ann Intern Med 106: 79–84, 1987.CrossRefPubMedGoogle Scholar
  600. a.Steinberg AD, Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34:945–950, 1991. (See also: Correspondence, 35:605–607, 1992.)Google Scholar
  601. 568.
    Sztejnbok M, Stewart A, Diamond H, et al.: Azathioprine in the treatment of systemic lupus erythematosus: a controlled study. Arthritis Rheum 14: 639–645, 1971CrossRefPubMedGoogle Scholar
  602. 569.
    Ginzler E, Sharon E, Diamond H, et al.: Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum 18: 27–35, 1975.CrossRefPubMedGoogle Scholar
  603. 570.
    Barnett EV, Dornfeld L, Lee DB, et al.: Long-term survival of lupus nephritis patients treated with azathioprine and prednisone. J Rheum 5: 275–287, 1978.PubMedGoogle Scholar
  604. 571.
    Felson DT, Anderson J: Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 311: 1528–1533, 1984.CrossRefPubMedGoogle Scholar
  605. 572.
    Drinkard JP, Stanley TM, Dornfeld L, et al.: Azathioprine and prednisone in the treatment of adults with lupus nephritis. Medicine 49: 411–432, 1970.CrossRefPubMedGoogle Scholar
  606. 573.
    Shelp WD, Bloodworth JMB Jr, Riselbach RE: Effect of azathioprine on renal histology and function in lupus nephritis. Arch Intern Med 128: 566–573, 1971.CrossRefPubMedGoogle Scholar
  607. 574.
    Hayslett JP, Kashgarian M, Cook CD, et al.: The effect of azathioprine on lupus glomerulonephritis. Medicine 51: 393–412, 1972.CrossRefPubMedGoogle Scholar
  608. 575.
    Hahn B, Kantor O, Osterland K: Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Ann Intern Med 83: 592–605, 1975.CrossRefGoogle Scholar
  609. 576.
    Donadio JV, Holley KE, Wagoner RD, et al.: Further observations in the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Arthritis Rheum 17: 573–581, 1974.CrossRefPubMedGoogle Scholar
  610. 577.
    Steinberg AD, Plotz PH, Wolf SM, et al.: Cytotoxic drugs in treatment of nonmalignant diseases. Ann Intern Med 76: 619–642, 1972.CrossRefGoogle Scholar
  611. 578.
    Schneck SA, Penn I: De-novo brain tumors in renal transplant recipients. Lancet 1: 983–986, 1971.CrossRefPubMedGoogle Scholar
  612. 579.
    Tallent MB, Simmons RL, Najarian JS: Birth defects in child of male recipient of kidney transplant. JAMA 211: 1854–1855, 1970.CrossRefPubMedGoogle Scholar
  613. 580.
    Malkzedah MH, Grushkin CM, Wright HT Jr. et al.: Hepatic dysfunction after renal transplantation in children. J Pediatr 81: 279–285, 1972.CrossRefGoogle Scholar
  614. 581.
    Balow JE, Boumpas DT, Vaughan EM, et al.: Lupus nephritis (LN): Controlled trial of pulse methylprednisolone (MP) versus pulse cyclosphosphamide (CY). J Amer Soc Neph 2: 263, 1991.Google Scholar
  615. 582.
    Wagner-Weiner L, Emery H, Spencer C, et al.: Intravenous pulse cyclophosphamide therapy (IVCY) for childhood lupus nephritis; Variable renal outcomes at 3 to 7 year follow-up. Arthritis Rheum 34: S58, 1991.Google Scholar
  616. 583.
    Austin HA III, Klippel JH, Balow JE, et al.: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614–619, 1986.CrossRefPubMedGoogle Scholar
  617. 584.
    Lehman TJA, Sherry DD, Wagner-Weiner L, et al.: Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 114: 1055–1060, 1989.CrossRefPubMedGoogle Scholar
  618. 585.
    McCune WJ, Golbus J, Zeldes W, et al.: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 318: 1423–1431, 1988.CrossRefPubMedGoogle Scholar
  619. 586.
    McCune WJ, Fox D: Intravenous cyclophosphamide therapy of severe SLE. Rheum Dis Clin NA 15: 455–477, 1989.Google Scholar
  620. 587.
    Boumpas DT, Yamada H, Patronas NJ, et al.: Intermittent pulse cyclophosphamide for the treatment of severe neuropsychiatric lupus. Arthritis Rheum 335: 130, 1990.Google Scholar
  621. 588.
    Reed WP, Lucas ZJ, Cohn R: Alternate-day prednisone therapy after renal transplantation. Lancet 1: 747–749, 1970.CrossRefPubMedGoogle Scholar
  622. 589.
    Walron J, Watson BS, Ney RL: Alternate-day vs. shorter-interval steroid administration. Arch Intern Med 126: 601–607, 1970.CrossRefGoogle Scholar
  623. 590.
    Jacobson ME: The rationale of alternate-day corticosteroid therapy. Postgrad Med 49: 181–187, 1971.PubMedGoogle Scholar
  624. 591.
    McAdams AJ, McEnery PT, West CD: Mesangiocapillary glomerulonephritis: changes in glomerular morphology with long-term alternate-day prednisone therapy.J Pediatr 86: 23–31, 1975.Google Scholar
  625. 592.
    Bolton WK, Atuk NO, Sturgill BC, et al.: Therapy of the idiopathic nephrotic syndrome with alternate-day steroids. Am J Med 62: 60–70, 1977.CrossRefPubMedGoogle Scholar
  626. 593.
    Fauci AS: Alternate-day corticosteroid therapy. Am J Med 64: 729–731, 1978.CrossRefPubMedGoogle Scholar
  627. 594.
    Coggins CH (ed.) A controlled study of short-term prednisone treatment in adults with membranous nephropathy: collaborative study of the adult idiopathic nephrotic syndrome. N Engl J Med 301:1301–1306, 1979.Google Scholar
  628. 595.
    Breitenfeld RV, Hebert LA, Lemann J, et al.: Stability of renal transplant function with alternate-day corticosteroid therapy. JAMA 244: 151–156, 1980.CrossRefGoogle Scholar
  629. 596.
    Macgregor RR, Sheagren JN, Lipsett MB, et al.: Alternate-day prednisone therapy: evaluation of delayed hypersensitivity responses, control of disease and steroid side effects. N Engl J Med 280: 1427–1431, 1969.CrossRefPubMedGoogle Scholar
  630. 597.
    McEnery PT, Gonzzlez LL, Martin LW, et al.: Growth and development of children with renal transplants. Use of alternate-day steroid therapy. J Pediatr 83: 806–814, 1973.CrossRefPubMedGoogle Scholar
  631. 598.
    Dale DC, Fauci AS, Wolff SM: Alternate-day prednisone: leucocyte kinetics and susceptibility to infections. N Engl J Med 291: 1154–1158, 1974.CrossRefPubMedGoogle Scholar
  632. 599.
    Shaprio GG, Tuttoni DS, Kelley VC, et al.: Growth, pulmonary, and endocrine function in chronic asthma patients on daily and alternate day adrenocorticoid therapy. J. Allergy Clin Immunol 57: 430–439, 1976.CrossRefGoogle Scholar
  633. 600.
    Bass AR, Kopelman R, McMahon D, et al.: High dose alternate-day steroid (HDADS) therapy in lupus nephritis. Arthritis Rheum 335: 164, 1990.Google Scholar
  634. 601.
    Kimura Y, Foeldvari I, Jacobs JC. Azathioprine is a valuable agent in the treatment of pediatric lupus nephritis. Pediatr Res 29 (#4, pt 2): 345A, 1991.Google Scholar
  635. 602.
    Rothenberg RJ, Graziano FM, Grandone JT, et al.: The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 31: 612–615, 1988.CrossRefPubMedGoogle Scholar
  636. 603.
    Lemoine R, Favre H, Miescher P, et al.: Morphological evolution of membranous lupus glomerulonephritis on combined treatment of cyclosporine and steroids. Kidney Int 37: 442, 1990.Google Scholar
  637. 604.
    Seaman WE, Ishak KG, Plotz PH: Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann Intern Med 80: 1–8, 1974.CrossRefPubMedGoogle Scholar
  638. 605.
    Ruppert GB, Barth WF: Tolmetin-induced aseptic meningitis. JAMA 245: 6768, 1981.CrossRefGoogle Scholar
  639. 606.
    Codding C, Targoff IN, McCarty GA: Aseptic meningitis in association with diclofenac treatment in a patient with systemic lupus erythematosus. Arthritis Rheum 34: 1340–1341, 1991.PubMedGoogle Scholar
  640. 607.
    Lehman TJA: Current concepts in immunosuppressive drug therapy of systemic lupus erythematosus. J Rheumatol 19: 20–22, 1992.Google Scholar
  641. 608.
    Gordon MF, Stolley PD, Schinnar R: Trends in recent systemic lupus erythematosus mortality rates. Arthritis Rheum 24: 762–765, 1981.CrossRefPubMedGoogle Scholar
  642. a.Oster MW: Oral Ondansetron. Ann intern Med 115: 233, 1991.Google Scholar
  643. 609.
    Orta-Sibu N, Chantler C, Bewick M, Haycock G: Comparison of high-dose intravenous methylprednisolone with low-dose oral prednisolone in acute renal allograft rejection in children. Br Med J 285: 258–260, 1982.CrossRefGoogle Scholar
  644. 610.
    Liebling MR, McLaughlin K, Boonsue S, et al.: Monthly pulses of methylprednisolone in SLE nephritis. J Rheumatol 9: 543–548, 1982.PubMedGoogle Scholar
  645. 611.
    Barron KS, Person DA, Brewer EJ Jr, et al.: Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr 101: 137–141, 1982.CrossRefPubMedGoogle Scholar
  646. 612.
    Hoch S, Schur PH: Methylprednisolone pulse therapy for lupus nephritis: a follow-up study. Clin Exp Rheumatol 2: 313–320, 1984.PubMedGoogle Scholar
  647. 613.
    Edwards JCW, Snaith ML, Isenberg DA: A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment. Ann Rheum Dis 46: 773–776, 1987.CrossRefPubMedGoogle Scholar
  648. 614.
    Singer DRJ, Roberts B, Cohen J: Infective complications of plasma exchange: a prospective study: Arthritis Rheum 30: 443–447, 1987.PubMedGoogle Scholar
  649. 615.
    Schroeder JO, Euler HH, Loftier H, Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 107: 344–346, 1987.CrossRefPubMedGoogle Scholar
  650. 616.
    Mackworth-Young CG, Morgan DSH, Hughes GRV: A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus. Ann Rheum Dis 47: 496–502, 1988.CrossRefPubMedGoogle Scholar
  651. 617.
    Balow JE: Lupus nephritis: pathogenesis, course and management. Adv Exp Med Biol 252: 3–15, 1989.CrossRefPubMedGoogle Scholar
  652. a.Lewis EJ, Hunsicker LG, Lan S-P, et al.: A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Eng J Med 326:1373–9, 1992. (See also Editorial, pp 1425–1427).Google Scholar
  653. 618.
    Aptekar RG, Atkinson JP, Decker JL, et al.: Bladder toxicity with chronic oral cyclophosphamide therapy in non-malignant disease. Arthritis Rheum 16: 46 1467, 1973.Google Scholar
  654. 619.
    Warne GL, Fairley KF, Hobbs JB, et al.: Cyclophosphamide-induced ovarian failure. N Engl J Med 289: 1159–1162, 1973.CrossRefPubMedGoogle Scholar
  655. 620.
    Tannenbaum H, Schur PH: Development of reticulum cell sarcoma during cyclophosphamide therapy. Arthritis Rheum 17: 15–18, 1974.CrossRefPubMedGoogle Scholar
  656. 621.
    Pollock BH, Barr JH Jr, Stolzer BL, et al.: Neoplasia and cyclophosphamide. Arthritis Rheum 16: 524–526, 1973.CrossRefGoogle Scholar
  657. 622.
    Walker SE, Anver MR: Accelerated appearance of neoplasia in female NZB/ NZW mice treated with high-dose cyclophosphamide. Arthritis Rheum 22: 1338–1343, 1979.CrossRefPubMedGoogle Scholar
  658. 623.
    Petri M, Perez-Gutthann S, Longenecker C, Hochberg MC: The association of black race with morbidity in patients with systemic lupus erythematosus (SLE) is explained by socioeconomic status (SES) and compliance. Arthritis Rheum 33S: 83, 1990.Google Scholar
  659. 624.
    Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M: Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status. Am J Med 91: 345–353, 1991.CrossRefPubMedGoogle Scholar
  660. 625.
    Liang MH, Partridge AJ, Daltroy LH, et al.: Strategies for reducing excess morbidity and mortality in blacks with systemic lupus erythematosus. Arthritis Rheum 34: 1187–1196, 1991.CrossRefPubMedGoogle Scholar
  661. 626.
    Samanta A, Feehally J, Roy S, et al.: High prevalence of systemic disease and mortality in Asian subjects with systemic lupus erythematosus. Ann Rheum Dis 50: 490–492, 1991.CrossRefPubMedGoogle Scholar
  662. 627.
    Sidel VW: Nephrology in the inner city. NYS J Med 9: 179–182, 1991.Google Scholar
  663. 628.
    Verrier Jones J, Fraser ID, Bothamley J, et al.: A therapeutic role for plasmapheresis in the management of acute systemic lupus erythematosus. Plasma Ther 1: 33–41, 1979.Google Scholar
  664. 629.
    Lockwood CM, Worlledge S, Nicholas A, et al.: Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 300: 524–530, 1979.CrossRefPubMedGoogle Scholar
  665. 630.
    Terman DS, Buffaloe G, Mattioli C, et al.: Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet 2: 824–827, 1979.CrossRefPubMedGoogle Scholar
  666. 631.
    Nossent JC, Swaack TJG, Berden JHM, et al.: Systemic lupus erythematosus after renal transplantation: Patient and graft survival and disease activity. Ann Intern Med 114: 183–188, 1991.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Jerry C. Jacobs
    • 1
  1. 1.Section of Pediatric Rheumatology and the Regional Arthritis Program (RAP-4-Kids)Columbia-Presbyterian Medical CenterNew YorkUSA

Personalised recommendations